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I. INTRODUCTION 
Subject to approval by the United States District Court for the Southern 
District of New York (the “Court”), this Settlement Agreement and Release (“Settlement 
Agreement,” “Settlement” or “Agreement”) sets forth the full and final terms by which 
the Class Representatives Amy Velez, Penni Zelinkoff, Minel Hider Tobertga, Michelle 
Williams, Jennifer Waxman-Recht, Karen Liggins, Lori Horton, Holly Waters, Wendy 
Pinson, Roberta Vonlintel, Catherine White, Kelly Corbett, Jamie Holland, Joan Durkin, 
Simona Lopes, Maryanne Jacoby and Marta Deyne (collectively “Class Representatives” 
or “Named Plaintiffs”), on behalf of a settlement class of themselves and current and 
former female sales force employees of Novartis Pharmaceuticals Corporation 
(“Novartis,” “Defendant,” or “Company”) (collectively, the “Settlement Class”), 
represented by their attorneys, Sanford Wittels & Heisler, LLP and the Law Offices of 
Grant E. Morris, and Defendant Novartis, represented by its attorneys Cravath, Swaine & 
Moore LLP, Vedder Price and Kaye Scholer LLP (collectively, “Counsel for Novartis” or 
“Counsel for Defendant”), have settled and resolved all claims that have been raised or 
could have been raised in the litigation captioned Velez, et al. v. Novartis 
Pharmaceuticals Corporation, Case No. 04 Civ. 9194, before District Judge Colleen 
McMahon in the United States District Court for the Southern District of New York (the 
“Civil Action”). 
II. DEFINITIONS 
The terms described below shall have the meanings defined in this Section 
wherever used in this Agreement, and for the purposes of this Agreement only, including 
in all of its Exhibits and the Notice of Class Action Settlement. 
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2.1 “Settlement Agreement” or “Agreement” means this Agreement and all 
Exhibits attached hereto. 
2.2 The “Civil Action” means the litigation captioned Velez, et al. v. Novartis 
Pharmaceuticals Corporation, Case No. 04 Civ. 9194, before Judge Colleen McMahon in 
the United States District Court for the Southern District of New York. 
2.3 “Claimant” for compensatory damages means a Proposed Settlement Class 
Member who has submitted a Claim Form for review by the Claims Adjudicator. 
2.4 “Claims Administrator” means the Claims Administrator appointed by the 
Court. 
2.5 “Claims Adjudicator” means the Claims Adjudicator appointed by the 
Court. 
2.6 “Claim Form” means the form attached hereto as Exhibit B. The Claim 
Form shall be attached to the Notice of Class Action Settlement and must be submitted by 
Proposed Settlement Class Members to the Claims Administrator as part of the claims 
process of this Settlement pursuant to Section X. Unless otherwise noted, the definition of 
“Claim Form” is inclusive of the Rider attached to the Claim Form. 
2.7 “Class Counsel” means the law firm of Sanford Wittels & Heisler, LLP. 
2.8 “Class Representatives” or “Named Plaintiffs” means Amy Velez, Penni 
Zelinkoff, Minel Hider Tobertga, Michelle Williams, Jennifer Waxman-Recht, Karen 
Liggins, Lori Horton, Holly Waters, Wendy Pinson, Roberta Vonlintel, Catherine White, 
Kelly Corbett, Jamie Holland, Joan Durkin, Simona Lopes, Maryanne Jacoby and Marta 
Deyne. 
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2.9 “Counsel for Novartis” or “Counsel for Defendant” means the law firms 
of Cravath, Swaine & Moore LLP, Vedder Price, and Kaye Scholer LLP. 
2.10 The “Court” means the United States District Court for the Southern 
District of New York. 
2.11 “Defendant”, the “Company” or “Novartis” means Novartis 
Pharmaceuticals Corporation. 
2.12 “Effective Date” means the date upon which all of the following have 
occurred: (1) entry of an order by the Court certifying the Settlement Class; (2) entry of an 
order or orders by the Court granting Final Approval to the Agreement, approving the 
amount of attorneys’ fees and costs and dismissing the Civil Action with prejudice; (3) the 
period for Novartis to withdraw from the Agreement pursuant to Section XI has expired 
(i.e., 30 calendar days from the Claims Administrator’s receipt of all timely and complete 
requests for exclusion submitted by a Class Representative and/or Proposed Settlement 
Class Member), and (4) the time for appeal has expired and/or if an appeal is taken, the 
appeal results in affirmance of the Court’s Final Approval Order of the Settlement 
Agreement. 
2.13 “Eligible Claimant” for compensatory damages means a Claimant who has 
submitted a timely and complete Claim Form to the Claims Administrator for review by the 
Claims Adjudicator. 
2.14 “Final Approval Date” or “Final Approval” means the date of entry by the 
Court of the Final Approval Order for this Settlement. 
2.15 “Medical Professional” means a physician or clinical psychologist. 
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2.16 “Notice of Class Action Settlement” means the notice attached hereto as 
Exhibit A. The Notice of Class Action Settlement shall be provided to the Settlement Class 
in accordance with Section X.D. 
2.17 “Parties” means the Class Representatives and Defendant. 
2.18 “Preliminary Approval Date” means the date of entry of the Preliminary 
Approval Order. 
2.19 “Preliminary Approval Order” means the Order entered by the Court 
preliminarily approving the terms of this Agreement, certifying the Settlement Class, and 
preliminarily approving the payment of attorneys’ fees, attorneys’ costs and the Service 
Award Payments, as described in this Agreement, scheduling a “Final Fairness Hearing”, 
and directing the mailing to the Settlement Class of the Notice of Class Action Settlement. 
2.20 “Released Claims” means any and all past or present claims or causes of 
action (including any suits, petitions, demands or other claims in law, equity or arbitration), 
and any and all allegations of liability or damages, of whatever kind, nature or description, 
direct or indirect, in law, equity or arbitration, absolute or contingent, whether class or 
individual in nature, including both known claims and Unknown Claims, asserted or 
unasserted, for monetary and non-monetary relief (including without limitation attorneys’ 
fees, costs or disbursements incurred by the Class Representatives and/or Proposed 
Settlement Class Members or their counsel in connection with or related to the Civil 
Action), that were or could have been asserted by the Class Representatives and/or 
Proposed Settlement Class Members against Novartis, its parents, subsidiaries, affiliates, 
predecessors, successors and/or assigns and in the case of all such entities, their respective 
past and present owners, representatives, officers, directors, attorneys, agents, employees, 
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privies and insurers (collectively defined as the “Released Parties”), based upon or arising 
out of the same events, transactions, series of connected transactions, occurrences or 
nucleus of operative facts that form the basis of the claims that were or could have been 
asserted in the Civil Action, including any and all claims asserted in the original and 
subsequently amended complaints filed in the Civil Action. This Release includes all 
claims based upon or arising out of the conduct alleged in the Complaint (including all 
Amended Complaints) or within the trial record. This Release includes any and all past or 
present claims or causes of action (including any suits, petitions, demands or other claims in 
law, equity or arbitration), and any and all allegations of liability or damages, of whatever 
kind, nature or description, direct or indirect, in law, equity or arbitration, absolute or 
contingent, whether class or individual in nature, including both known claims and 
Unknown Claims, asserted or unasserted, for monetary and non-monetary relief (including 
without limitation attorneys’ fees, costs or disbursements incurred by the Class 
Representatives and/or Proposed Settlement Class Members or their counsel in connection 
with the Civil Action), that were or could have been asserted by the Class Representatives 
and Proposed Settlement Class Members against the Released Parties based upon, or arising 
in any way out of the litigation of the Civil Action or the jury verdict, provided however 
that nothing contained herein shall prevent any Party to this Settlement Agreement from 
initiating a legal action to enforce any term or provision of this Settlement Agreement. 
Specifically included in this release are any and all claims, including both known claims 
and Unknown Claims, that were or could have been asserted in the Civil Action, including 
but not limited to, claims of alleged employment discrimination, sexual harassment claims, 
hostile work environment claims or benefits claims under Title VII of the Civil Rights Act 
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of 1964, 42 U.S.C. § 1981a, and any other applicable federal, state, or local statutes, 
common law, or regulation. Furthermore, this Release includes all claims for monetary 
damages, injunctive, declaratory or equitable relief, and costs and attorneys’ fees, whether 
arising under Title VII, Section 1981a or under any other federal, state, local or common 
laws or regulations arising out of the same transactions, series of connected transactions, 
occurrences or nucleus of operative facts that form the basis of the claims, including both 
known claims and Unknown Claims, that were or could have been asserted in the Civil 
Action. This Release does not include or cover any actions or omissions occurring after the 
Preliminary Approval Date, nor does it include or cover any claims stemming from any 
certified class action, other than this Civil Action, of which the individual is already a 
member either by virtue of opting-in under 29 U.S.C. § 216(b) or because the class is 
certified under Rule 23(b)(2) and/or Rule 23(b)(3). 
2.21 The “Settlement Class” means a class certified by the Court for settlement 
purposes pursuant to Federal Rules of Civil Procedure 23(b)(2) and (b)(3) consisting of all 
women who are currently holding, or have held, a sales-related position of Sales 
Representatives, Sales Consultants, Senior Sales Consultants, Executive Sales Consultants, 
Sales Associates, Sales Specialists, Senior Sales Specialists or District Managers I with 
Novartis Pharmaceuticals Corporation, from the start of the class period, July 15, 2002, 
through the Preliminary Approval Date (together the “Proposed Settlement Class Members” 
or “Settlement Class Members” and each a “Proposed Settlement Class Member” or 
“Settlement Class Member”), excluding individuals who entered into individual releases as 
part of individual agreements with Novartis up to the Preliminary Approval Date that did 
not carve out an exception for this Civil Action. 
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2.22 The “Settlement Class Period” shall be defined as July 15, 2002 through 
the Preliminary Approval Date. 
2.23 “Unknown Claims” means any and all Released Claims which any Named 
Plaintiff or Proposed Settlement Class Member does not know or suspect to exist in her 
favor at the time of the release of the Released Parties, which if known by her might have 
affected her decision(s) with respect to the Settlement. With respect to any and all Released 
Claims, the Parties stipulate and agree that upon the Effective Date, the Named Plaintiffs 
shall expressly waive, and each Proposed Settlement Class Member shall be deemed to have 
waived, and by operation of the Final Approval Order shall have expressly waived, any and 
all provisions, rights and benefits conferred by any law of any state or territory of the 
United States, or principle of common law, which is similar, comparable, or equivalent to 
Cal. Civ. Code § 1542, which provides: 
“A general release does not extend to claims which the creditor does not 
know or suspect to exist in his or her favor at the time of executing the 
release, which if known by him or her must have materially affected his or 
her settlement with the debtor.” 
The Parties acknowledge, and all other Proposed Settlement Class Members by operation of 
law shall be deemed to have acknowledged, that the inclusion of “Unknown Claims” in the 
definition of Released Claims was separately bargained for and was a key element of the 
Settlement. 
III. NATURE AND RESOLUTION OF THIS CASE 
3.1 On November 19, 2004, Class Representatives Amy Velez and four other 
women filed a Class Action Complaint against Novartis Corporation and Novartis 
Pharmaceuticals Corporation in the United States District Court for the Southern District of 
New York, on behalf of themselves and a nationwide class of female sales force employees 
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of Novartis under Title VII, 42 U.S.C. § 2000(e) et seq. An additional thirteen women were 
subsequently added as Class Representatives. The Class Representatives filed their Second 
Amended Class Action Complaint on June 3, 2005, their Third Amended Class Action 
Complaint on September 9, 2005 and their Fourth Amended Class Action Complaint on 
March 13, 2006. 
3.2 On January 16, 2007, the Class Representatives filed their Motion to 
Certify a Class. Novartis submitted a brief in opposition to class certification on March 22, 
2007. On July 31, 2007, the Court certified a class action pursuant to Rule 23(b)(2). On 
August 16, 2007, the Court issued an Amended Opinion and Order, and issued notice of 
court approval of class certification on December 7, 2007. The notice was addressed to all 
women who were employed in certain sales-related positions with Novartis in the period 
between July 15, 2002, and November 30, 2007. 
3.3 A jury trial commenced on April 7, 2010. The jury delivered a verdict on 
behalf of Plaintiffs on all counts and awarded compensatory and punitive damages. The 
trial concluded on May 19, 2010, with equitable relief and non-monetary relief to be 
ordered by the Court at a later date. 
3.4 The Parties agree that the settlement described in this Agreement is fair, 
reasonable and adequate. Class Counsel and the Class Representatives represent that the 
settlement set forth in this Settlement Agreement is the product of vigorous and lengthy 
negotiations and serves the best interest of the Proposed Settlement Class based on all the 
facts and circumstances because it provides certain, prompt and extensive relief for the 
Proposed Settlement Class and avoids the risk of future litigation. 
8 
3.5 It is the intention of the Parties to fully, finally, and forever settle, 
compromise, and discharge all disputes and claims of the Proposed Settlement Class, 
whether asserted or unasserted, based on, arising from or related in any way to the Civil 
Action. 
3.6 It is the intention of the Parties that this Agreement shall constitute a full 
and complete settlement and release of all claims of the Proposed Settlement Class against 
the Defendant that were or could have been asserted as based on or arising from the Civil 
Action, and that the Civil Action shall be dismissed with prejudice. 
3.7 Defendant denies all claims as to liability, wrongdoing, damages, 
penalties, interest, fees, injunctive relief and all other forms of relief, as well as the class 
allegations asserted in the Civil Action. Defendant has agreed to resolve the Civil Action in 
this Agreement, but to the extent this Agreement is deemed void or the Effective Date does 
not occur, Defendant does not waive, but rather expressly reserves, all rights to challenge 
any and all claims and allegations asserted by the Class Representatives in the Civil Action 
upon all procedural and substantive grounds, including, without limitation, the ability to 
challenge class action treatment on any grounds and to assert any and all potential defenses 
or privileges. The Class Representatives and Class Counsel agree that Defendant retains 
and reserves these rights, and they agree not to take a position to the contrary. Specifically, 
the Class Representatives and Class Counsel agree that, if the Civil Action were to proceed, 
they will not present any argument based on this Settlement or Settlement Agreement, or 
any exhibit, attachment, act performed or document executed pursuant to this Settlement or 
this Agreement. Additionally, neither the Agreement nor the Settlement, nor any act 
performed or document executed pursuant to, or in furtherance of, the Agreement or the 
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Settlement: (a) is or may be deemed to be or may be used as an admission or evidence of 
the validity of any Released Claim, or of any wrongdoing or liability of the Released 
Parties, or any of them; or (b) is or may be deemed to be or may be used as an admission or 
evidence of any fault or omission of the Released Parties, or any of them, in any civil, 
criminal or administrative proceeding in any court, administrative agency or other tribunal. 
3.8 Neither this Agreement nor anything in it, nor any part of the negotiations 
that occurred in connection with the creation of this Settlement, shall constitute evidence 
with respect to any issue or dispute in any lawsuit, legal proceeding or administrative 
proceeding, except for legal proceedings concerning the enforcement or interpretation of 
this Agreement. 
IV. MUTUAL FULL COOPERATION 
4.1 The Parties agree that they will fully cooperate with each other to 
effectuate and implement all terms and conditions of this Settlement Agreement, and 
exercise good faith efforts to accomplish the terms and conditions of this Settlement 
Agreement. 
V. RELEASES 
5.1 Upon the Effective Date of this Settlement Agreement, in consideration 
for the agreements by the Parties and other good and valuable consideration, the receipt and 
sufficiency of which is hereby acknowledged, all Named Plaintiffs and each and every 
member of the Proposed Settlement Class, on behalf of themselves, their heirs, executors, 
administrators, predecessors, successors and assigns shall hereby release, remise and 
forever discharge the Released Parties (as defined above) from each and every Released 
Claim (as defined in Paragraph 2.20 above), and shall forever be barred and enjoined from 
initiating, continuing, filing or otherwise prosecuting any Released Claim against any of the 
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Released Parties and their counsel, whether or not the claims of the Proposed Settlement 
Class Members have been approved, allowed, substantiated or rejected. Unless a Named 
Plaintiff or Proposed Settlement Class Member opts out of the Settlement pursuant to 
Paragraph 10.28 below, this Release shall apply whether or not such individual has 
executed and delivered a Claim Form or otherwise actively participated in the Settlement. 
5.2 Every Proposed Settlement Class Member, as defined above (except for 
those who opt out pursuant to Paragraph 10.28 below), shall be deemed to and shall have 
knowingly and voluntarily waived, released, discharged and dismissed the Released Claims, 
with full knowledge of any and all rights they may have, and they hereby assume the risk of 
any mistake in fact in connection with the true facts involved, or with regard to any facts 
which are now unknown to them. 
5.3 The Parties and Proposed Settlement Class Members acknowledge that the 
covenants and promises made by Novartis herein constitute adequate consideration in 
exchange for the Released Claims. 
5.4 Nothing in this Settlement Agreement shall be construed to bar any claims 
of Proposed Settlement Class Members or the Class Representatives based on or arising out 
of events occurring after the Preliminary Approval Date by the Court of the Settlement 
Agreement. Nor shall anything in this Settlement Agreement be construed to bar any 
claims of Proposed Settlement Class Members or the Class Representatives based on or 
arising out of claims in any certified class action, other than this Civil Action, of which the 
individual is already a member either by virtue of opting-in under 29 U.S.C. § 216(b) or 
because the class is certified under Rule 23(b)(2) and/or Rule 23(b)(3). 
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VI. TOTAL SETTLEMENT AMOUNT 
6.1 The “Total Settlement Amount,” in full and complete satisfaction of all 
Released Claims, shall be up to $175,000,000.00 in monetary and non-monetary relief, 
comprised of a cash payment of up to $152,500,000.00 (the “Settlement Fund”) and 
programmatic non-monetary relief, described in Section VII, valued at $22,500,000.00. 
6.2 Subject to Court approval, the Settlement Fund will be provided to the 
Claims Administrator to be distributed as described in Sections VIII, IX and X of this 
Agreement. 
VII. PROGRAMMATIC RELIEF 
7.1 The programmatic relief described in this Section will be effective 
immediately upon the Effective Date and shall remain binding on the Parties and their 
agents and successors for a three-year period following the Effective Date or until the Court 
determines that Novartis is in compliance with the programmatic relief in this Section. 
7.2 Novartis will substantially comply with the programmatic relief described 
in this Section within one (1) year of the Effective Date. 
7.3 The monitoring period for the relief described in this Section, with 
reporting to Class Counsel and the Compliance Master as described below in Section VII.H 
will be three (3) years from the Effective Date, and with the first report due one (1) year 
following the Effective Date. 
7.4 If Novartis’s compliance is satisfactory to the Court, Novartis’s 
obligations with respect to the programmatic relief described in this Section will end upon 
the Court’s order. 
7.5 The terms of the programmatic relief described in this Section will be 
subject to good-faith negotiation between the Parties, should there be a legitimate business 
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reason to modify those terms. No substantive modification may be made to the terms of 
this Section absent approval by the Court. 
7.6 Nothing in this Section shall be construed to require or permit any party to 
the Agreement, or agent thereof, to disclose Novartis’s confidential personnel information. 
7.7 Novartis agrees to take the actions described in this Section with respect to 
employees who hold positions as Sales Representatives, Sales Consultants, Senior Sales 
Consultants, Executive Sales Consultants, Sales Associates, Sales Specialists, Senior Sales 
Specialists, and District Managers I. 
A. Proactive Equal Employment Opportunity Measures. 
7.8 Novartis will take the following actions regarding the following aspects of 
the field force employment experience: 
(i) Novartis will include, as part of its bi-annual employee 
engagement survey (or a separate add-on for employees in jobs covered by this 
Agreement) conducted anonymously by an outside survey provider, questions about 
work-life balance, including questions concerning the comfort level that employees have 
in using pregnancy leave, job share policies and the sexual harassment policy regarding 
inappropriate sexual behavior or comments by physician customers, as well as the 
attitudes employees have observed management expressing regarding maternity leave 
and job share policies. This survey, which is conducted by a well-known third-party 
specialist, is next scheduled for the second calendar quarter of 2011. 
(ii) Sexual Harassment Policy and Training: Novartis will prepare and 
circulate a sexual harassment policy that will cover inappropriate conduct by employees 
and physician customers and will make clear that Novartis does not tolerate inappropriate 
sexual behavior or comments by physician customers. Novartis will conduct annual 
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training on this policy, which includes guidance to the field force regarding how to 
respond if faced with inappropriate sexual behavior, as well as direction to employees to 
report such conduct for investigation and remedial action. The bi-annual survey 
described in Paragraph 7.8(i) will elicit feedback from all Novartis employees regarding 
whether they understand the policy and would be comfortable reporting inappropriate 
conduct under this policy. 
7.9 Novartis will track the trends in response to the survey described in 
Paragraph 7.8(i). With respect to Paragraph 7.8(ii), Novartis will continue its zero tolerance 
policy of permanently removing any physician who was the subject of a substantiated 
employee complaint for conduct constituting sexual harassment from both the target calling 
list and the incentive goals for all sales representatives. 
7.10 Novartis will report the results of the bi-annual survey described in 
Paragraph 7.8(i) to the Compliance Committee (whose membership includes the Vice 
President of Ethics and Compliance, President of Novartis, and the Heads of several 
different departments and Business Units) and that Committee will make recommendations, 
where needed, to remedy as soon as practicable any gender-related problems affecting 
employees covered by this Agreement and evidenced in the survey. Those 
recommendations, along with the survey responses and the trends over the years, will be 
delivered on a bi-annual basis. In addition, Novartis will provide a brief summary to Class 
Counsel of any action taken by the Compliance Committee to remedy the problems 
discussed above. 
B. Responses to Complaints of Discrimination. 
7.11 Within nine months following the Effective Date of this Agreement, 
Novartis will increase the size of both the Human Resources Business Partners staff and the 
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Employee Relations and Human Resources Compliance Group (“Employee Relations” or 
the “Employee Relations Group”), which is designated to respond to and investigate 
complaints of discrimination. 
(i) The ratio of each Employee Relations investigator to number of 
employees can be no less than 1 investigator-to-1000 employees, in line with external 
best practices benchmarks (2009 Corporate Leadership Council). 
(ii) The ratio of each Human Resources Business Partner to number of 
employees can be no less than 1 Partner -to-210 employees, in line with external best 
practices benchmarks (2009 Corporate Leadership Council). 
(iii) The Head of Employee Relations responsible for overseeing all 
investigations regarding complaints of discrimination must report directly to the Vice 
President of Human Resources. 
7.12 Novartis will revise the policies and processes regarding its investigation 
into discrimination as follows: 
(i) An additional resource for reporting complaints will be 
established. Novartis will institute a new “hotline” specific to Employee Relations 
complaints that would be directed immediately to Novartis’s Head of Employee 
Relations, with a copy to the Business Practices Officer (“BPO”) for tracking and formal 
assignment of investigative authority. 
(ii) Novartis will communicate to employees its policy that requires all 
employees to immediately report—to the BPO, Employee Relations Hotline, Alertline, 
his or her Supervisor, an officer of the Company, or a representative of Human 
Resources, Ethics and Compliance or Legal—all complaints of misconduct. Novartis 
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will also communicate to employees its policy that requires managers or upper-level 
Novartis employees to immediately report—to the BPO, Employee Relations Hotline, 
AlertLine, his or her Supervisor, an officer of the Company, or a representative of Human 
Resources, Ethics and Compliance or Legal—all complaints of misconduct made by 
others, and that management may not exercise its discretion regarding whether or not to 
report such a complaint. 
(iii) Novartis will track the date and time that all complaints are 
received by the BPO and the date that the BPO assigns the complaint to the Employee 
Relations Group for investigation. Novartis will also track the date and time that all 
complaints are received by the Employee Relations hotline and copied to the BPO for 
tracking and formal assignment of investigative authority. 
(iv) Novartis will establish a policy that all complaints of 
discrimination received by the BPO be assigned to the Employee Relations Group for 
investigation within two (2) business days of the BPO’s receipt of the complaint. 
(v) The Employee Relations Group will reach out to the complaining 
individual insofar as he or she is known and reachable within two (2) business days of 
receiving the complaint, and maintain a record of the date that the complaining individual 
is contacted. 
(vi) The response time of the Employee Relations Group will be 
reviewed by the Head of Employee Relations on a quarterly basis. If the Employee 
Relations Group fails to meet the two-day requirement in any two (2) consecutive 
quarters, Novartis will hire one (1) additional Employee Relations investigator. 
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7.13 As a part of any Employee Relations investigation, the Employee 
Relations investigator may attempt to conduct a follow-up interview with the complainant 
where appropriate and necessary to the investigation (including any counter-claims and 
defenses and the opportunity for the complainant to respond thereto). 
(i) This follow-up interview, if conducted, will take place after the 
Employee Relations investigator has conducted an investigation into the corroboration of 
or defenses against the discrimination complaint and has reviewed any relevant 
documentation. 
7.14 At the conclusion of the investigation, the Employee Relations Group will 
notify the complaining individual that the investigation has been closed, what the result of 
the investigation was (substantiated, unable to conclude, not substantiated), and the 
complainant’s rights upon conclusion of the investigation. 
7.15 Novartis will disseminate to the entire sales field force on an annual basis 
the following clarifications and explanations regarding the Employee Relations process: 
(i) Novartis will explain clearly and in writing that employees may 
make complaints on an anonymous basis (and will point out that anonymity might, in 
some instances, constrain the ability to investigate), and that the information collected 
during the investigation is kept confidential to the extent possible. 
(ii) Novartis will explain clearly and in writing the process followed 
by Employee Relations regarding investigations into complaints of discrimination, the 
possible outcomes where claims are substantiated, that the timeline for an investigation is 
dependent on the particular facts of the case, the role that a complainant will play in the 
process, that a complainant may at all times communicate with Employee Relations 
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either orally or in writing, and the level of information provided to the complainant at the 
close of an investigation. 
7.16 Novartis has developed a formalized complaint investigation process, 
which it will continue to follow, including the practice that all investigative steps taken by 
the Employee Relations Group either be made in writing or documented after the fact. 
Novartis will further maintain an electronic database of any complaints—substantiated, 
unable to conclude or unsubstantiated—and disciplinary action taken (if any), so that 
decisionmakers have access to disciplinary guidance from similar cases so as to ensure 
consistent responses across the Company. One purpose of the database will be to identify 
trends, and to determine what additional training or policy adjustments are required in areas 
including gender equity. 
(i) Novartis will ensure that all management-level employees and 
above are fully trained on this investigation process annually. 
(ii) Novartis will ensure that all Employee Relations and Human 
Resources Business Partners are fully trained annually on this investigation process. 
(iii) Novartis will explain clearly and in writing that there are several 
factors for management to consider in making disciplinary decisions, including the type 
of misconduct, severity, harm to the complainant and whether there have been multiple or 
sequential substantiated or unable to conclude complaints. A copy shall be provided to 
Class Counsel. 
(iv) Novartis will continue to ensure that Field Management does not 
have full discretion regarding whether a claim is sufficiently substantiated, the 
appropriate discipline and any appropriate corrective steps when necessary. To that end, 
18 
Novartis will continue to empower a Resolution Committee consisting of representatives 
from Legal, Employee Relations, the Ethics and Compliance Department and Human 
Resources to review the findings and make recommendations about corrective action (up 
to and including termination) to the relevant management. In forming its 
recommendation, the Resolution Committee will have access to the database described 
in Paragraph 7.19 below, so as to obtain, among other things, information related to prior 
substantiated and/or unable to conclude complaints against the subject of the 
investigation. If field management disagrees with the recommendation made by the 
Resolution Committee, the matter is escalated to the Novartis Compliance Officer, Head 
of the relevant Business Unit and the Resolution Committee for final decision. The Vice 
President of Human Resources will review the escalated matter in the event of further 
disagreement. 
C. Human Resources’ Role in Clarification Meetings. 
7.17 Within six months of the Effective Date of the Agreement, Novartis will 
revise the timing and function of the “clarification meeting” as follows: 
(i) Novartis will provide the employee who is the subject of the 
complaint the opportunity to provide any evidence to the investigator within two (2) 
business days after the clarification meeting. If the employee submits such additional 
evidence and requests a follow-up meeting, a subsequent clarification meeting or 
telephone conference will be held before the Resolution Committee makes any 
determination. 
(ii) The Resolution Committee will consider any evidence presented 
by the employee in making its recommendations. 
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D. Oversight and Implementation. 
7.18 Upon the Effective Date of this Agreement, Novartis will immediately 
commence the process of preparing training for all Employee Relations and Human 
Resources Business Partner personnel regarding all changes made in accordance with this 
Agreement. Novartis anticipates the roll-out of training will commence approximately one 
(1) year later, and the Company will put forth best efforts to commence training even earlier 
if it is practicable to do so. 
7.19 Novartis currently maintains, and will continue to maintain, a database of 
all complaints that the Employee Relations Group investigates which includes: 
(i) the date of the complaint, 
(ii) the type of complaint, 
(iii) the complainant (where available), 
(iv) the identity of the subject of the complaint, 
(v) the investigator assigned, 
(vi) the date of the initial contact with the complainant, 
(vii) the outcome of the investigation (unsubstantiated, unable to 
conclude, or substantiated), and 
(viii) the nature of the corrective action, if any. 
7.20 The investigation file contains: 
(i) dates of interviews, 
(ii) date of clarification meeting[s], and 
(iii) date of Resolution Committee meeting. 
20 
7.21 Novartis will build into the investigation process identification at the 
inception of the investigation whether the subject of the complaint has been the subject of 
any prior complaints. 
7.22 The Head of Employee Relations will compile an annual report to be 
delivered to the Compliance Committee with one copy to the Chairman of the Novartis 
Pharmaceuticals Corporation Board of Directors. Each annual report will relay the contents 
of the databases detailed above, including an assessment of any gender-related trends 
evidenced in that data, and a summary of the nature and resolution of complaints. 
E. Performance Evaluations. 
Novartis agrees to the following actions with respect to its Performance 
Evaluation Process: 
7.23 Clarification and Implementation of the Performance Evaluation 
(i) Novartis will evaluate how to ensure that an employee’s leave of 
absence will not result in negative performance ratings for his/her manager, his/her 
counterparts in the territory and the employee in question. 
(ii) Novartis will develop and issue specific guidance regarding 
implementation of the Values and Behaviors evaluation. 
a) Such guidance shall include examples of conduct that 
represents “1,” “2” or “3” in each value and behavior, and descriptors of “not meeting”, 
“meeting” and “exceeding” expectations. 
b) It will also include detailed parameters regarding what each 
number score means, how to differentiate among the scores, and how to appropriately 
determine an overall score from the subscores so that employees are assessed 
consistently. 
21 
(iii) Novartis will develop and issue guidance regarding the 
implementation of the Objective Evaluation. 
(iv) Values and Behaviors Training: Novartis will conduct training of 
all managers on how to assess Values and Behaviors in light of the specific guidance 
described above. 
(v) Objective Training: Novartis will provide training and written 
guidance to all managers on defining the factors that will be considered as relevant Key 
Performance Indicators (“KPIs”) and the weight given to each KPI, and how leaves of 
absence will be handled when evaluating sales results. In addition, Novartis will instruct 
managers that consideration and application of mitigating factors will take place at the 
calibration sessions. 
(vi) Novartis will provide training to employees and managers on 
completing their self-assessments and the role that multi-raters play in the performance 
management process. 
(vii) Novartis will retain an external specialist with the input of Class 
Counsel (who shall first review the qualifications of this individual, including previous 
analyses and publications). This specialist will design an annual adverse impact analysis 
of ratings to determine if there are any significant gender disparities. 
a) Class Counsel shall have an opportunity to meet with the 
specialist and review his/her proposed methodology as well as the final methodology 
used for the analysis before the specialist begins the analysis. 
b) Class Counsel shall also have the opportunity to make 
recommendations to the specialist about the methodology used for the analyses. 
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c) Novartis agrees to share the results of that analysis, as they 
pertain to gender, with Class Counsel. Class Counsel shall have the opportunity to 
propose recommendations to Novartis on appropriate remedies. Novartis will remedy, as 
soon as practicable, any gender-related problems affecting employees covered by this 
Agreement and evidenced in the analysis. 
7.24 Transparency and Training 
(i) Novartis will provide mandatory training for all managers 
regarding the performance evaluation process, including the specific guidance discussed 
above. This same training will be made optional for sales force members and provided 
on the Novartis intranet. 
(ii) The sales force will receive and have access to all written guidance 
regarding performance evaluations that are made available to managers. 
(iii) Novartis will continue to circulate to all associates at year-end all 
written guidance for performance evaluations, including information regarding the 
appeals process (see Paragraph 7.26 below). This information will continue to be made 
available on the Novartis intranet. 
7.25 Calibration Sessions 
(i) Novartis will conduct calibration sessions at the District Manager 
and second-line manager level for representatives (and at the second-line manager and 
Vice President level for District Managers) to ensure consistency in the evaluation of 
employees against a uniform understanding of the expectations. 
a) Human Resources will continue to play an active role in the 
calibration sessions as detailed below. 
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b) Each second-line manager will meet with all of his or her 
District Managers along with an Human Resources representative to discuss the uniform 
expectations for performance at each level, any mitigating circumstances that came into 
play for any districts in the region, and application of the uniform expectations to the 
sales representatives across districts. 
c) The Human Resources representative will be primarily 
responsible for presenting the uniform expectations; the second-line manager will lead 
the other portions of the discussion. 
d) The Human Resources representative will be tasked with 
maintaining records on the conversations had during the calibration session and the 
reasons for any alterations to ratings that are made as a result of the conversation. Any 
disputes between a District Manager and a second-line manager must also be 
documented. 
e) The same process will be followed at one level up for the 
evaluation of District Managers. 
7.26 Human Resources’ Role and the Appeals Process 
(i) Novartis will add an appeals process whereby employees who 
disagree with their performance rating may appeal to their 1 over 1 manager who, in 
consultation with an Human Resources Business Partner who was not involved in the 
calibration session, will render a final decision. 
(ii) Any employee who believes that his/her review was improperly 




Novartis agrees to the following actions with respect to its Compensation Policies 
and Procedures: 
7.27 Novartis Compensation and Benefits (“C&B”) will work with an external 
C&B specialist to design a Base Salary pay in range analysis and subsequent adverse impact 
analysis, as described below. Novartis will retain the specialist with the input of Class 
Counsel (who shall first review the qualifications of this individual, including previous 
analyses and publications). 
(i) Class Counsel shall have an opportunity to meet with the specialist 
and review his/her proposed methodology as well as the final methodology used for the 
analyses below before the specialist begins the analysis. 
(ii) Class Counsel shall also have the opportunity to make 
recommendations to the specialist about the methodology used for the analyses. 
7.28 Novartis C&B will work with the specialist to design a base salary pay in 
range analysis for sales representatives and first-line managers. 
(i) This analysis will include identification of any gender-related 
discrepancies within the range despite similar tenure, experience, and performance. 
(ii) The analysis will be completed within three months after the 
agreed analysis design. In case of discrepancy versus range, Novartis will bring the 
outliers within range within 18 months according to a phased schedule. 
7.29 The specialist will review the Field Force Incentive policy to avoid 
negative impact on Incentive payout for managers or for sales representatives as a result of 
approved leaves of absence for other sales representatives in the district. 
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7.30 Novartis has introduced a merit increase grid, which limits a manager’s 
discretion on pay decisions and should be used as a guideline for pay increases. The grid 
shows a matrix with Position in Range and Performance Rating and for each position, a 
range of recommended pay increase (as a percentage). Managers will be required to 
document any deviation from the grid. The C&B manager will review the recommended 
merit increases against the guidelines and make a final recommendation for approval to 
senior management. These recommendations shall be documented in writing. 
7.31 Guidelines on how to plan for merit increases will be issued prior to the 
year-end process. A manager’s merit increase planning will be reviewed by the Supervisor, 
Human Resources and the C&B team. 
7.32 Upon completion of each annual merit planning process, Novartis C&B 
will perform an adverse impact analysis for discrepancies in annual rate of pay based on 
gender. 
(i) Novartis will make necessary adjustments based on these findings 
in the next merit cycle. 
a) Adjustments resulting from the adverse impact analysis 
will not be taken from the merit increase budget established for that year. 
(ii) For the term of this Agreement, Novartis agrees to share the results 
of that analysis, as they pertain to gender, with Class Counsel. Class Counsel shall have 
the opportunity to propose recommendations to Novartis for compensation adjustments 
detailed in Paragraph 7.32(i) above. 
7.33 Any employee who believes that his/her merit raise or compensation is 
tainted by discrimination, may file a complaint in accordance with the Employee Relations 
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complaint process. Novartis will provide in writing a reminder of the complaint process on 
an annual basis. 
G. Promotional Opportunities. 
Novartis agrees to the following actions with respect to its Policies and 
Procedures for Promotional Opportunities: 
7.34 Formalizing and Articulating Standards 
(i) Novartis has formalized and documented the qualifications 
necessary to be considered eligible for management, the processes followed for 
management development, the steps a representative must take to become a manager, and 
the role that the District Manager and second-line manager play in that process. In 
instances where employees are assigned to District Manager positions outside the process 
because the position is filled by external hiring, international hiring, or by a 
developmental rotation, Novartis will ensure this is done on a non-discriminatory basis. 
a) Novartis will provide written direction and training that 
specifies that District Managers and second-line managers are not allowed to modify or 
add any additional requirements, standards, or steps to the Management Development 
(“MD”) process. 
b) On an annual basis, Novartis will provide these policies in 
written form to the entire sales field force and will make them available year-round on 
the Novartis intranet. 
c) Novartis will also provide clear written materials regarding 
the pre-Management Development Program (“MDP”) checklist and the MD classes, how 
each stage progresses, what individuals need to do to move through each stage, and the 
frequency at which each of the MD classes are offered. 
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d) Where possible, the calendared dates for each MD class, 
along with the eligibility requirements and the registration process, should be posted on 
the intranet well in advance of registration closing for each class. 
e) Employees will be notified of a Sales Training department 
employee who can answer questions regarding the MD classes and the MDP checklist. 
Novartis will ensure that this department is sufficiently staffed to answer questions in a 
timely manner. 
(ii) MDP Training 
a) Novartis will commit that the MDP will not require more 
than a three-night stay away from home per quarter for training on the MDP, and will not 
require training to occur over the weekend. 
7.35 Enabling More Self-Guided Development 
(i) Novartis has created and will continue to maintain a system that 
allows interested employees to self-register their interest in management electronically. 
a) In response to a registration of interest for management, 
Novartis does, and will continue to, automatically provide to the eligible individual 
information regarding completion of the MDP checklist, along with eligibility 
requirements and the next steps in proceeding through the MDP process. These materials 
will also detail what changes in performance or other circumstances would lead to an 
employee being removed from the MDP process. 
b) Novartis will also provide a Sales Training contact who can 
answer questions about the process and can provide advice regarding concerns. 
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c) The Sales Training contact will monitor candidates’ 
progress through the program and if concerns are identified either by a candidate or by 
the Sales Training contact himself/herself, will notify the appropriate Human Resources 
Business Partner. The Human Resources Business Partner will intervene as necessary 
and discuss with the District Manager and/or second-line manager any concerns 
regarding the support of the District Manager or second-line manager for management. 
d) Any concerns regarding discrimination will be handled 
pursuant to the Employee Relations complaint process. 
(ii) A second-line manager will be required to monitor the progress of 
employees who participate in the Management Development system. 
(iii) Novartis will maintain a distribution list of “ready” management 
candidates, updated after the close of each MD3 class, who have completed the MD 
process and so are eligible for a District Manager I position. Unless an available District 
Manager I position must be filled under exigent circumstances that require an immediate 
hiring decision or will be filled through external hiring, international hiring, or by a 
developmental rotation, Novartis will post available District Manager I positions on its 
internal system. Candidates may set up a profile which will have the system 
automatically notify them when such a posting appears. 
7.36 Tracking and Monitoring Progress 
(i) Novartis will create and maintain a database that tracks the overall 
number, identity and gender of individuals who self-nominate, have completed 
the checklist and have completed each of the MD classes (MD1, MD2 or MD3). 
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a) The database will also identify the date at which each step 
in the process was completed. 
b) The database will also record the number and gender 
distribution of each individual who became a District Manager I by year and the date and 
position which each individual filled. 
c) Individuals will remain in the database until they are no 
longer with the Company, become a District Manager, move into a different Novartis 
career path (e.g., marketing), no longer satisfy the performance or other requirements for 
a District Manager I position, or have removed themselves from consideration. 
(ii) Novartis will retain an external specialist to design an adverse 
impact analysis two years from the Effective Date of this Agreement with respect to the 
pool of employees qualified for and interested in promotions to first-line manager to 
determine if there are any significant gender disparities in overall gender representation at 
the District Manager I level, in new hires into the District Manager I level, and in time to 
promotion into District Manager I from completion of MD3. Novartis will retain the 
specialist with the input of Class Counsel (who shall first review the qualifications of this 
individual, including the previous analyses and publications). 
a) Class Counsel shall have an opportunity to meet with the 
specialist and review his/her proposed methodology as well as the final methodology 
used for the analysis before the specialist begins the analysis. 
b) Class Counsel shall also have the opportunity to make 
recommendations to the specialist about the methodology used for the analysis. 
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c) This analysis will be conducted in accordance with federal 
affirmative action guidelines. 
d) Novartis agrees to share the related results of that analysis, 
as they pertain to gender, with Class Counsel. Class Counsel shall have the opportunity 
to propose recommendations to Novartis on appropriate remedies. Novartis will remedy, 
as soon as practicable, any gender-related problems affecting employees in jobs covered 
by this Agreement and evidenced in the analysis. 
(iii) Novartis will compile an annual report to be provided to the Head 
of Human Resources, the Vice President of Diversity and the Executive Committee, with 
one copy to the Chairman of the Novartis Pharmaceuticals Corporation Board of 
Directors. Each annual report will relay the contents of the database detailed above in 
Paragraph 7.36(i). 
7.37 Cultivating Talent 
(i) Novartis will work with Luke Visconti, CEO from DiversityInc, 
and Joyce Dudley from Dudley Hamilton to work on the overall culture at Novartis and 
improve the Novartis work environment for all employees and report annually to the 
Novartis Executive Committee on recommendations and actions taken. 
H. Compliance. 
7.38 The Court will appoint, pursuant to Federal Rule of Civil Procedure 53 
(“Rule 53”), a Compliance Master to monitor the implementation by Novartis of the terms 
of Section VII of this Agreement. 
7.39 For each of the three (3) years following the Effective Date, Novartis will 
submit, on the anniversary of the Effective Date, an annual report to Class Counsel detailing 
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its compliance with Section VII of this Agreement and attaching any expert reports 
generated during the course of the preceding year. Within thirty (30) calendar days of the 
submission of each annual report, Novartis and Class Counsel will jointly submit to the 
Compliance Master Novartis's annual report (including attachments), as well as either a 
joint statement that the Parties agree that Novartis has complied with Section VII of this 
Agreement, or a statement by Class Counsel identifying areas of Novartis's alleged 
noncompliance with Section VII of this Agreement and an accompanying response by 
Novartis. 
7.40 If Class Counsel identifies areas of alleged noncompliance, or if the 
Compliance Master deems it necessary and appropriate notwithstanding the Parties’ 
agreement as to compliance, the Compliance Master shall make written inquiries to the 
Parties to assess whether there are compliance issues. The Parties will respond in writing to 
any such inquiries within thirty (30) days of the date of the mailing of the written inquiries, 
and the Compliance Master shall then, within thirty (30) days of receipt of the Parties’ 
written response, conclude in writing either that Novartis is in compliance with Section VII 
of this Agreement or inform the Parties of any specific item or items as to which Novartis is 
not in compliance. 
7.41 The Compliance Master shall be responsible only for identifying any 
noncompliance with the specific terms of Section VII of this Agreement; however, the 
Compliance Master may make suggestions regarding the means by which Novartis might 
bring itself into compliance. 
(i) If the Compliance Master determines that Novartis is in 
compliance with the terms of Section VII of this Agreement for that year, no further 
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reporting action regarding that year shall be necessary. However, if the Compliance 
Master concludes that Novartis is in compliance with Section VII of this Agreement, 
Class Counsel may file objections to that conclusion with the Court pursuant to Rule 53 
no later than twenty (20) days after a copy of the conclusion is served on Class Counsel. 
(ii) If the Compliance Master identifies a specific item or items on 
which Novartis is not in compliance, Novartis shall promptly take remedial steps to bring 
itself into compliance. In the alternative, Novartis may file objections to the Compliance 
Master's conclusion with the Court pursuant to Rule 53 no later than twenty (20) days 
after a copy of the Compliance Master's conclusion is served on Novartis. 
a) In the event that Novartis is required to take remedial steps 
to bring itself into compliance, Novartis shall provide a supplemental report detailing the 
remedial steps taken and explaining how these steps remedied the identified areas of non-
compliance. This supplemental report shall be provided to the Compliance Master on a 
timeline to be set by the Compliance Master at the time any instance of noncompliance is 
identified. 
b) Class Counsel shall have an opportunity to comment no 
later than twenty (20) days after a copy of Novartis’s supplemental report is served on 
Class Counsel and the Compliance Master. The Compliance Master shall then either 
conclude that Novartis is in compliance or that it is not. 
7.42 Upon completion of the third annual report cycle, as described above, if 
the Compliance Master believes that Novartis is in compliance with Section VII of this 
Agreement, he or she shall recommend to the Court that Novartis’s obligations described in 
this Section be terminated. If at that time the Compliance Master does not believe that 
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Novartis is in compliance with Section VII of this Agreement or is not satisfied that 
Novartis has promptly corrected any specific items of noncompliance, he or she shall make 
a recommendation to the Court concerning the possible extension of all or some of 
Novartis’s obligations under Section VII of this Agreement. Pursuant to Rule 53, the 
Parties may file comments or objections to the Compliance Master’s recommendation with 
the Court no later than twenty (20) days after a copy of the Compliance Master’s 
recommendation is served. 
7.43 The fees and costs of the Compliance Master, which shall not exceed 
$250,000.00 for the three-year period, shall be paid from the Settlement Fund as an 
administrative expense, as described in Paragraph 9.6 below. 
7.44 Any information obtained by the Compliance Master shall be treated as 
confidential and shall not be used for any purpose other than monitoring the implementation 
of this Agreement, consistent with the terms of Section VII. Prior to receiving the Parties’ 
first annual report, the Compliance Master shall execute a confidentiality agreement limited 
by the restriction in the preceding sentence. 
7.45 Nothing in this Provision will limit the right of Class Counsel to 
participate in the implementation or oversight of the Programmatic Relief as is otherwise 
detailed in Section VII of this Agreement. 
VIII. SETTLEMENT FUND 
8.1 No later than thirty (30) calendar days after the Effective Date, Novartis 
shall provide, by wire transfer, to the Claims Administrator $152,500,000.00 (the 
“Settlement Fund”). The Settlement Fund is calculated based upon the Total Settlement 
Amount described in Paragraph 6.1 ($175,000,000.00) minus the value of the non-monetary 
relief portion of the Settlement described in Section VII ($22,500,000.00). 
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8.2 The Settlement Fund will be placed in an interest bearing account (the 
“Settlement Fund Account”) approved by Class Counsel with a unique Taxpayer 
Identification Number. Any interest accrued prior to the distribution of any monetary 
awards will be divided equally between the Class Award for Backpay and the Maximum 
Class Award for Compensatory Damages, described in Paragraphs 10.1(iii) and (iv) below, 
and distributed according to the procedures set forth therein. 
8.3 The Settlement Fund Account will constitute a qualified settlement fund 
pursuant to Internal Revenue Code Section 1.468B-1. Upon the opening of the account, 
Novartis shall execute an election statement provided by the Claims Administrator which 
shall be affixed to the initial tax return of the Settlement Fund Account in order to establish 
the start date of the Settlement Fund Account. The Settlement Fund Account will be 
created, managed and disbursed by the Claims Administrator under the supervision of Class 
Counsel and Counsel for Novartis. The Claims Administrator shall be the only entity 
authorized to make withdrawals or payments from the Settlement Fund Account. Novartis 
will have no responsibilities or liabilities with respect to the administration of the 
Settlement Fund Account, including any distribution therefrom and the reporting for such 
distribution. 
8.4 Upon wiring the Settlement Fund amount, Novartis will have no further 
monetary obligations with respect to Settlement Class Members, Class Counsel or Named 
Plaintiffs pursuant to the Settlement and shall have no further responsibility to make any 
additional payments pursuant to this Settlement, including with respect to attorneys’ fees 
and costs. 
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8.5 The Claims Administrator shall have the obligation to return the entire 
Settlement Fund (including all income and/or interest generated by the Settlement Fund 
Account) to Novartis within five (5) business days in the event of revocation of this 
Settlement pursuant to Section XI below, or in the event that this Settlement Agreement is 
reversed on appeal or is otherwise rendered null and void for any reason. 
8.6 The Claims Administrator shall distribute the Settlement Fund (including 
any interest generated by the Settlement Fund Account) pursuant to the provisions below, 
and on the time schedule described herein and pursuant to orders of the Court. 
8.7 In the event that the Settlement Fund is not completely distributed for any 
reason, any and all remaining funds shall revert back to Novartis. The Claims 
Administrator shall provide, by wire transfer, the amount to be reverted to Novartis no later 
than ten (10) business days after the distribution of the settlement checks described in 
Section X.J below. In addition, within one (1) year and fifteen (15) business days from the 
date of distribution of the settlement checks described in Section X.J below, the Claims 
Administrator shall provide to Novartis, by wire transfer, the amount of any settlement 
checks not paid from the Settlement Fund Account due to Settlement Class Members’ 
failure to cash the check within one (1) year. The Claims Administrator’s determination of 
the amount to revert back to Novartis pursuant to this provision shall be final and non-
appealable. 
8.8 $164,500.00 of the Settlement Fund will be set aside in a fund to be 
distributed to a non-profit organization dedicated to the advancement of women in the 
workforce. The choice of such organization will be proposed by Class Counsel to Novartis, 
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who may reject Class Counsel’s choice and require alternative proposals until Class 
Counsel proposes an organization that meets Novartis’s approval. 
IX. ATTORNEYS’ FEES AND EXPENSES, ADMINISTRATIVE EXPENSES 
AND SERVICE AWARD PAYMENTS 
A. Attorneys’ Fees and Expenses. 
9.1 Pursuant to Fed. R. Civ. P. 23(h), Class Counsel, in connection with 
seeking Court approval of the Settlement, shall apply for reasonable attorneys’ fees and 
expenses incurred by Class Counsel, including the fees and expenses in connection with 
overseeing the claims process and monitoring the Settlement Agreement. 
9.2 Novartis will not object to a motion for attorneys’ fees by Class Counsel 
of up to $38,125,000.00. Novartis will not object to a motion for expenses by Class 
Counsel of up to $2,000,000.00. These amounts include all fees, costs and expenses in 
connection with the Civil Action and overseeing the claims process and monitoring the 
Settlement Agreement. 
9.3 The Claims Administrator will pay from the Settlement Fund any Class 
Counsel attorneys’ fees and expenses ordered by the Court no later than thirty-five (35) 
calendar days after the Effective Date. Prior to the payment of attorneys’ fees and 
expenses, Class Counsel will provide the Claims Administrator with Tax Payer 
Identification Numbers for Class Counsel and executed Form W-9s. Form 1099s shall be 
provided to Class Counsel for the payments made to Class Counsel. Class Counsel agrees 
that any allocation of fees between or among Class Counsel shall be the sole responsibility 
of Class Counsel. 
9.4 If the Court awards attorneys’ fees in an amount less than $38,125,000.00 
and/or expenses in an amount less than $2,000,000.00, the difference will be divided and 
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allocated in equal parts to the Class Award for Backpay and the Maximum Class Award 
for Compensatory Damages, described in Paragraphs 10.1(iii) and (iv) below, and 
distributed according to the procedures set forth therein. If the Court awards attorneys’ 
fees in an amount greater than $38,125,000.00 and/or expenses in an amount greater than 
$2,000,000.00, the difference shall be deducted in equal parts from the Class Award for 
Backpay and the Maximum Class Award for Compensatory Damages, described in 
Paragraphs 10.1(iii) and (iv) below. 
B. Administrative Expenses. 
9.5 No later than ten (10) business days after the deadline for completion of 
the entire claims process, the Claims Administrator and Claims Adjudicator shall provide 
the Court and Counsel for the Parties with a statement detailing their respective fees, costs 
and expenses incurred in connection with administering the Settlement Fund. The Parties 
agree to cooperate in the settlement administration process and to make all reasonable 
efforts to control and minimize the costs and expenses incurred in the administration of the 
Settlement. The Claims Administrator and Claims Adjudicator will be paid for the above-
referenced fees and expenses from the Settlement Fund. 
9.6 $250,000.00 of the Settlement Fund will be set aside to pay the fees and 
costs of the Compliance Master as set forth in Paragraph 7.43 above. In the event that the 
total fees and costs of the Compliance Master are less than $250,000.00, the difference will 
be distributed to the non-profit organization chosen by the Parties pursuant to Paragraph 8.8 
above. It is the Parties’ intention that the costs and expenses incurred in the administration 
of the Settlement, including the fees and costs of the Compliance Master, not exceed 
$2,375,000.00. 
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C. Service Award Payments and Compensatory Damages to Named Plaintiffs 
and Testifying Witnesses 
9.7 Subject to Court approval, the Claims Administrator will pay from the 
Settlement Fund prescribed amounts to deponents, testifying witnesses and Named 
Plaintiffs for the substantial time and energy that they have devoted in litigating this 
lawsuit, provided they do not opt-out of the Settlement (collectively “Service Award 
Payments”). 
(i) Subject to Court approval, the following amounts shall be 
distributed to the Testifying Witnesses and Named Plaintiffs to compensate each 
individual for compensatory damages and for their dedicated service in litigating the 
matter and bringing about this Settlement: 
• Tara Blum (Testifying Witness): $205,000.00; 
• Jessica Borsa (Testifying Witness): $425,000.00; 
• Kelly Corbett (Testifying Witness and Named Plaintiff): $363,000.00; 
• Marta Deyne (Named Plaintiff): $385,000.00; 
• Bernice Dezelan (Testifying Witnes): $272,000.00; 
• Joan Durkin (Named Plaintiff): $385,000.00; 
• Minel Hider Tobertga (Named Plaintiff): $385,000.00; 
• Jamie Holland (Named Plaintiff): $385,000.00; 
• Lori Horton (Named Plaintiff): $385,000.00; 
• Maryanne Jacoby (Named Plaintiff): $385,000.00; 
• Terri Kelly (Testifying Witness): $175,000.00; 
• Karen Liggins (Named Plaintiff): $385,000.00; 
• Simona Lopes (Named Plaintiff): $385,000.00; 
• Christine Macarelli (Testifying Witness): $249,000.00; 
• Wendy Pinson (Named Plaintiff): $385,000.00; 
• Raelene Ryan (Testifying Witness): $425,000.00; 
• Marjorie Salame (Testifying Witness): $425,000.00; 
• Kelli Shannon (Testifying Witness): $325,000.00; 
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• Amy Velez (Lead Named Plaintiff): $410,000.00; 
• Roberta Von Lintel (Named Plaintiff): 385,000.00; 
• Holly Waters (Testifying Witness and Named Plaintiff): $425,000.00; 
• Jennifer Waxman-Recht (Testifying Witness and Named Plaintiff): $425,000.00; 
• Catherine White (Testifying Witness and Named Plaintiff): $331,500.00; 
• Michelle Williams (Named Plaintiff): $385,000.00; 
• Penni Zelinkoff (Named Plaintiff): $385,000.00; and 
• Amy Zschiesche (Testifying Witness): $260,000.00. 
The amounts above reflect a compensatory damage award for the Testifying Witnesses 
awarded by the jury (capped at $300,000.00 per statutory mandate), and for the non-
testifying Named Plaintiffs based on the average jury award to Named Plaintiffs. Two 
modifications to the compensatory damage awards were included for testifying 
individuals who had additional claims outside the original certified class period that are 
now included in the settlement period. Each amount also includes a $125,000.00 Service 
Award Payment, with Lead Named Plaintiff Amy Velez receiving a $150,000.00 Service 
Award Payment. 
(ii) Subject to Court approval, a Service Award Payment of 
$25,000.00 each shall be distributed to the deponents in compensation for their dedicated 
service in litigating the matter and bringing about this settlement: 
• Dana Allen • Michelle Kraft 
• Holly Blakeley • Julie Lynch 
• Donna Connally • Karla Palmer 
• Cassandra Covington • Jennifer Peldiak 
• Christine Coyle • Drew Persinger 
• Debora Davis • Carrie Petermeyer 
• Ivette Flower • Angela Plonczyk 
• Felicia Jordan • Theresa Thomas 
• Nicole Joslin • Heather Thompson 
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• Ryan Tselikis • Christine Vaughn 
Individuals receiving a Service Award Payment pursuant to this Paragraph must follow 
the claims procedure set out in Section X.E below. 
(iii) The Claims Administrator will pay the aforementioned Service 
Award Payments, less applicable withholdings and deductions, if any, within thirty-five 
(35) calendar days after the Effective Date. All individuals receiving payments under 
these paragraphs who are also Settlement Class Members, as defined in Paragraph 2.21 
above, are eligible to receive a backpay award pursuant to Paragraph 10.1(iii). 
9.8 If the Court awards monies less than those set out above, the difference 
will be divided and allocated in equal parts to the Class Award for Backpay and the 
Maximum Class Award for Compensatory Damages described in Paragraphs 10.1(iii) and 
(iv) below, and distributed according to the procedures set forth therein. If the Court 
awards monies more than those set out above, the difference shall be deducted in equal parts 
from the Class Award for Backpay and the Maximum Class Award for Compensatory 
Damages described in Paragraphs 10.1(iii) and (iv) below. 
X. INDIVIDUAL MONETARY PAYMENTS TO SETTLEMENT CLASS 
MEMBERS AND CLAIMS PROCESS 
A. Allocation of Individual Monetary Awards 
10.1 Individual Awards for Backpay and Compensatory Damages 
(i) Individual monetary awards payable to Proposed Settlement Class 
Members and Class Representatives will be allocated in settlement of their claims for 
backpay or lost wages and compensatory damages. Monetary awards for backpay or lost 
wages are subject to all applicable tax withholdings. Monetary awards for compensatory 
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damages and/or Service Award Payments shall not be treated as lost wages and therefore 
will be subject to reporting on IRS Form 1099. 
(ii) Payments made under this Agreement are not intended to and will 
not: (1) form the basis for additional contributions to, benefits under, or any other 
monetary entitlement under; or (2) be considered to apply to, or be applied for purposes 
of, Novartis’s bonus, executive compensation, pension, any 401(k) and/or other 
retirement, savings or benefit plans or similar programs. 
(iii) Backpay: $60,000,000.00 of the Settlement Fund (which includes 
the employer’s share of federal and state payroll taxes) (and any additional monies, or 
less any deductions, pursuant to Paragraphs 8.2, 9.4 and/or 9.8 above) will be allocated to 
the “Class Award for Backpay”, apportioned among the Class Representatives and 
Proposed Settlement Class Members who do not opt out of the settlement as follows: 
a) A fixed monthly amount for backpay (“Backpay Monthly 
Amount”) will be calculated by dividing the Class Award for Backpay by the total 
months worked by the Class Representatives and Proposed Settlement Class Members in 
jobs included within the Settlement Class definition in Paragraph 2.21 (“class-eligible 
job(s)”) during the Settlement Class Period. 
b) A Class Representative or Settlement Class Member who 
does not opt out of the settlement will receive an amount equal to the Backpay Monthly 
Amount multiplied by the number of months the Settlement Class Member worked in a 
class-eligible job during the Settlement Class Period, less applicable withholdings and 
deductions as described below in Paragraph 10.1(iii)(c). 
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c) The Claims Administrator will withhold from each Class 
Representative and Settlement Class Member’s backpay award both the employee’s and 
employer’s share of applicable taxes under federal, state and/or local laws. The Claims 
Administrator will ensure that such monies withheld are paid to the appropriate 
authorities for each Settlement Class Member and Class Representative and will issue 
IRS Forms W-2 for the amounts reportable on each Form. 
d) Any portion of the Class Award for Backpay that is not 
awarded or withheld through the process described in Paragraphs 10.1(iii)(a)-(c) will be 
apportioned to the Class Representatives and Settlement Class Members who do not opt 
out of the settlement in proportion to the number of months that each such person worked 
in a class-eligible job during the Settlement Class Period. No portion of the Class Award 
for Backpay will revert back to Novartis or be allocated to the Maximum Class Award 
for Compensatory Damages. 
(iv) Compensatory Damages: The Settlement Fund less distributions 
pursuant to Paragraph 8.8, Section IX and the Class Award for Backpay (and any 
additional monies, or less any deductions, pursuant to Paragraphs 8.2, 9.4 and/or 9.8 
above) will be allocated to the Maximum Class Award for Compensatory Damages, to be 
distributed as follows: 
a) A fixed monthly amount for compensatory damages 
(“Compensatory Monthly Amount”) will be calculated by dividing the Maximum Class 
Award for Compensatory Damages (currently estimated at approximately 
$40,000,000.00) by the total months worked by Proposed Settlement Class Members in 
class-eligible jobs during the Settlement Class Period. 
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b) A Proposed Settlement Class Member who is both 
(1) eligible to receive compensatory damages by submitting a timely and complete Claim 
Form pursuant to Paragraph 10.13 below (“Eligible Claimant”), and (2) deemed by the 
Claims Adjudicator to have substantiated her claim for compensatory damages pursuant 
to Section X.F, will receive an award of compensatory damages in an amount equal to the 
Compensatory Monthly Amount multiplied by the number of months the Eligible 
Claimant worked in a class-eligible job during the Settlement Class Period. 
c) In addition, an Eligible Claimant who was treated by a 
Medical Professional (as defined in Paragraph 2.15 above) during the period July 15, 
2002 to the Preliminary Approval Date for pain and suffering resulting from gender 
discrimination she experienced while working in a class-eligible job, and who timely 
completes the requirements set forth below in Paragraph 10.15, may be entitled to an 
increase in her compensatory award above the amount determined pursuant to Paragraph 
10.1(iv)(b). The amount of increase, if any, in an Eligible Claimant’s compensatory 
award will be determined by the Claims Adjudicator in his or her discretion and paid out 
of the Maximum Class Award for Compensatory Damages as defined above. The total of 
all additional compensatory damages awarded by the Claims Adjudicator pursuant to this 
provision shall not exceed $5,000,000.00. 
d) No Eligible Claimant may receive a compensatory award in 
an amount that exceeds the limitation on compensatory and punitive damages provided 
for by 42 U.S.C. § 1981a(b)(3)(D) (i.e., $300,000.00). 
e) Any portion of the Maximum Class Award for 
Compensatory Damages that is not awarded as a result of the claims process and 
44 
monetary distribution procedure described in Section X herein will revert back to 
Novartis pursuant to the procedure described in Paragraph 8.7 above. 
B. Claims Administrator’s Duties. 
10.2 The Claims Administrator shall (1) mail the Notice of Class Action 
Settlement (the “Notice”) and Claim Forms to Proposed Settlement Class Members; 
(2) respond to questions from Proposed Settlement Class Members; (3) perform backpay 
and compensatory award distribution calculations as set forth in Paragraph 10.1; 
(4) maintain a toll-free number for communicating with Proposed Settlement Class 
Members; (5) mail checks containing payments to Named Plaintiffs, deponents, testifying 
witnesses, Settlement Class Members, Class Counsel, and the Claims Administrator and 
Claims Adjudicator; (6) wire any amount from the Settlement Fund which reverts back to 
Novartis; (7) forward all compensatory damage Claim Forms received from Class Members 
to the Claims Adjudicator on a rolling basis; and (8) perform any other duties necessary to 
fulfill its responsibilities described in this Agreement. 
C. Claims Adjudicator. 
10.3 The Court shall appoint at least one Claims Adjudicator to (1) receive and 
review Claim Forms, any written responses from Novartis and any further information 
submitted by Class Counsel to evaluate eligibility and make a final determination regarding 
entitlement to compensatory awards; (2) receive and review the Riders to Claim Forms to 
evaluate eligibility and make a final determination regarding entitlement to increased 
compensatory awards and if so, the amount of such increased compensatory award; (3) seek 
additional information from Claimants or Class Counsel, when appropriate; and (4) report 
to the Court, the Claims Administrator and to all Counsel final determinations regarding 
entitlement to, and amount of, compensatory awards. 
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D. Notice and Claim Forms. 
10.4 Within twenty (20) business days after the Preliminary Approval Date, the 
Company shall provide to the Claims Administrator a list of all Proposed Settlement Class 
Members, including name, employee ID, job title, employment dates, last known address 
and telephone number. The Company will provide this information in a format reasonably 
acceptable to the Claims Administrator. The Claims Administrator will maintain this list in 
the strictest confidence and shall not disclose it to anyone except Class Counsel, who may 
use it only for purposes of administering this Settlement. Class Counsel may provide 
updates on any addresses or contact information provided by the Proposed Settlement Class 
Members to the Claims Administrator, and such updates shall be incorporated into the list. 
10.5 The Company’s existing personnel and payroll records shall be presumed 
to be correct as to any Claimant’s gender and dates of employment. In order to overcome 
such a presumption, a Claimant must, within twenty (20) calendar days of the mailing of the 
notice that her claim was denied, submit documentary evidence showing that the 
Company’s records are inaccurate and that corrected information should be used. 
10.6 No later than twenty (20) business days after the date that the Company 
provides the list of all Proposed Settlement Class Members described in Paragraph 10.4, the 
Claims Administrator shall mail the Notice of Class Action Settlement, in substantively the 
form attached hereto as Exhibit A, and as approved by the Court, to Proposed Settlement 
Class Members, by United States first class mail, postage prepaid with a postmark date 
stamped on the envelope of the Notice. The Parties intend to provide actual notice to each 
Proposed Settlement Class Member, to the extent practicable. The Claims Administrator 
shall mail a Claim Form, attached hereto as Exhibit B, to each Proposed Settlement Class 
Member at the same time the Notice is sent. 
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10.7 In order to provide the best notice practicable, the Claims Administrator 
will do the following before mailing the Notice and Claim Form: (1) run the list of all 
Proposed Settlement Class Members through the United States Postal Service’s National 
Change of Address database (“NCOA”); and (2) perform address searches using public and 
proprietary electronic resources which collect their data from various sources such as utility 
records, property tax records, motor vehicle registration records (where allowed) and credit 
bureaus. 
10.8 If envelopes from the mailing of the Notice and Claim Form are returned 
with forwarding addresses, the Claims Administrator will re-mail the Notice and Claim 
Form to the new address within three (3) business days of receiving the returned envelope. 
10.9 Class Counsel shall provide the Court, at least five (5) calendar days prior 
to the Final Fairness Hearing, a declaration by the Claims Administrator of due diligence 
and proof of mailing with regard to the mailing of the Notice of Class Action Settlement 
and Claim Form to Proposed Settlement Class Members. 
10.10 In the event that a Notice of Class Action Settlement and Claim Form are 
returned to the Claims Administrator by the United States Postal Service because the 
address of the recipient is no longer valid, i.e., the envelope is marked “Return to Sender”, 
the Claims Administrator shall perform a standard skip trace in an effort to attempt to 
ascertain the current address of the particular Proposed Settlement Class Member in 
question and, if such an address is ascertained, the Claims Administrator will re-send the 
Notice and Claim Form within three (3) business days of receiving the newly ascertained 
address; if no updated address is obtained for that Proposed Settlement Class Member, the 
Notice of Class Action Settlement and Claim Form shall be sent again to the Proposed 
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Settlement Class Member’s last known address. In either event, the Notice of Class Action 
Settlement and Claim Form shall be deemed received once it is mailed for the second time 
unless the Proposed Settlement Class Member can demonstrate good reason why she did 
not receive it. 
10.11 With respect to envelopes marked “Return to Sender”, the Claims 
Administrator will also call any identified last-known telephone numbers (and telephone 
numbers updated through public and proprietary databases) of Proposed Settlement Class 
Members to obtain their current addresses. 
10.12 The Claims Administrator shall provide to Counsel for Novartis and Class 
Counsel, at least ten (10) business days prior to the Final Fairness Hearing, a list of 
Proposed Settlement Class Members for whom notices were returned as undeliverable and 
for whom efforts to obtain an alternative address failed. 
E. Submission of Claim Forms After Final Approval. 
10.13 All Proposed Settlement Class Members who seek recovery of a monetary 
award from the Maximum Class Award for Compensatory Damages portion of the 
Settlement Fund must make such a claim in writing using the Claim Form attached as 
Exhibit B. All Claim Forms must be signed by the Claimant under penalties of perjury. 
Each Proposed Settlement Class Member who seeks to be considered as an “Eligible 
Claimant” must submit her own timely and complete Claim Form. All Claim Forms must 
be mailed to the Claims Administrator and postmarked by the claim filing deadline 
described in the Notice and Claim Form in order to be considered timely. In order for a 
Claim Form to be considered complete, all questions must be answered (except that failure 
to provide an employee identification number will not in any way be held against the 
Claimant) and all applicable blanks filled in in a manner legible to the Claims Administrator 
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and Claims Adjudicator. Failure to file a timely and complete Claim Form by the deadline 
for submission of all Claim Forms, if not corrected within the remedial period set forth in 
Paragraph 10.19 below, shall bar the Proposed Settlement Class Member from receiving a 
monetary award for compensatory damages. 
10.14 In the Claim Form, each Eligible Claimant who seeks recovery of a 
monetary award from the Maximum Class Award for Compensatory Damages portion of 
the Settlement Fund must declare under penalties of perjury (without a notarized 
requirement) that during the Settlement Class Period, while in a class-eligible job, she was 
discriminated against on account of her gender in seeking a promotion, in the level of her 
pay, and/or on account of pregnancy, and that she experienced physical and/or emotional 
pain and suffering resulting from that discrimination. The Eligible Claimant’s declaration 
must be accompanied by a reasonably detailed explanation of the circumstances giving rise 
to the belief that she experienced gender discrimination during the Settlement Class Period 
and a reasonably detailed explanation of the nature of the resulting physical and/or 
emotional pain and suffering. 
10.15 In the Rider to the Claim Form, each Eligible Claimant who seeks, 
pursuant to Paragraph 10.1(iv)(c), an increase in her compensatory award above the amount 
determined pursuant to Paragraph 10.1(iv)(b) must declare under penalties of perjury 
(without a notarized requirement) that she received medical treatment from a Medical 
Professional during the period July 15, 2002 to the Preliminary Approval Date for the 
physical and/or emotional pain and suffering the Eligible Claimant contends resulted from 
the gender discrimination alleged in her Claim Form. The Eligible Claimant’s declaration 
must be accompanied by a reasonable explanation of such medical treatment. The Eligible 
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Claimant must also attach to the Rider to the Claim Form a declaration executed by the 
Eligible Claimant’s Medical Professional declaring under penalties of perjury (without a 
notarized requirement): (1) that he or she provided medical treatment to the Eligible 
Claimant during the period July 15, 2002 to the Preliminary Approval Date for physical 
and/or emotional pain and suffering resulting from gender discrimination the Eligible 
Claimant experienced while working in a class-eligible job, and (2) describing the nature of 
the medical treatment provided to the Eligible Claimant. Novartis, Counsel for Novartis 
and Class Counsel shall not have access to any Claimant’s Rider to her Claim Form, or any 
declaration attached thereto. 
10.16 The Claims Administrator shall submit, on a weekly basis, a copy of all 
timely and complete Claim Forms, excluding the Rider, received as of that date to a 
designated Novartis representative (who shall not be part of Field Management or the 
Human Resources Department). If Novartis has information within its possession that is 
inconsistent with an Eligible Claimant’s declarations contained in her Claim Form, Novartis 
may submit a written response to the Claims Administrator and Claims Adjudicator, with a 
copy to Class Counsel, within forty-five (45) calendar days of the deadline for submission 
of all Claim Forms. No further submission shall be made by Novartis. If Novartis submits 
a written response to any Claim Form, Class Counsel may submit additional information to 
the Claims Administrator and Claims Adjudicator about the Eligible Claimant’s 
declarations in her Claim Form that are the subject of Novartis’s written response within 
fourteen (14) calendar days of the submission of Novartis’s written response. 
(i) Novartis’s written response may identify only the following 
categories of inconsistent information: dates of employment; positions held; dates of 
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application for any promotions; dates of completion of any course or training process; 
reporting relationships; dates of reported contact with Human Resources or Novartis 
management regarding a Claimant’s concerns or complaints; reported national and 
regional ranking of the individual Claimant; reported annual performance rating; 
Claimant’s compensation; Claimant’s leaves of absence, (including, but not limited to 
pregnancy leave and Family and Medical Leave), and any recorded Human Resources or 
BPO investigations into Claimant during the time period in which Claimant alleges 
discrimination. 
(ii) The designated Novartis representative will not respond with 
counter-allegations regarding: the substance or content of conversations between a 
Claimant and any Novartis employee; any assessment of the relative performance of any 
of Claimant’s peers; or any other assessment of the Claimant’s performance, reliability, 
or the merit of Claimant’s claims. 
(iii) The designated Novartis representative will prepare and provide 
any written responses to the Claim Forms submitted by Settlement Class Members. Field 
Management, including line-managers and one-over managers, will not be informed of 
any Claimant’s filing or involved in any way with the preparation of the response. 
(iv) Claim Forms shall be used only for the purpose of filing a claim 
for compensatory damages under this Agreement, and shall not be used by Settlement 
Class Members, Class Counsel or any other person for any other reason. Claim Forms 
may not be used by Novartis to conduct internal investigations in to the substance of the 
allegations contained therein. Accordingly, any Proposed Settlement Class Member who 
believes that she or anyone else is subject to ongoing discrimination or misconduct must 
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report their allegations separately to the Novartis Business Practices Officer (“BPO”) or 
to the Employee Relations hotline, AlertLine, her Supervisor, an officer of the Company, 
or a representative of Human Resources, Ethics and Compliance or Legal for 
investigation and resolution. 
(v) Claim Forms will be used only to administer the Settlement, and 
will not be admissible in a court or other legal proceeding for any other purpose. 
10.17 Proposed Settlement Class Members who file a Claim Form must notify 
the Claims Administrator of any change of address. A failure to notify the Claims 
Administrator of a change of address may result in the forfeiture of a monetary award for 
compensatory damages. The Claims Administrator shall be available through the toll-free 
line to respond to requests from Proposed Settlement Class Members for assistance in 
completing and filing Claim Forms. Class Counsel shall also be available to consult with 
and provide assistance to Proposed Settlement Class Members who request assistance in 
completing their Claim Forms. 
10.18 No untimely filed and/or incomplete Claim Forms may be accepted by the 
Claims Administrator, except that (1) the Claims Administrator may extend the deadline for 
receipt of Claim Forms by up to ten (10) additional calendar days (but no more) where error 
or delay by United States Postal Service is established; and/or (2) the Claims Administrator 
may provide a one-time extension of the deadline for receipt of Claim Forms of up to sixty 
(60) additional calendar days upon good cause shown. 
F. Administrative Review of All Claims. 
10.19 The Claims Administrator shall conduct a review of all Claim Forms, as 
well as data provided by Novartis and Class Counsel concerning the time period each 
52 
Claimant was employed by Novartis, to determine whether the Claim Form is sufficiently 
complete, as provided for in Paragraph 10.13. 
(i) If the Claims Administrator or Claims Adjudicator rejects a Claim 
Form as not meeting the terms or provisions of the Settlement Agreement, the Claims 
Adjudicator or Claims Adjudicator shall so notify the Claimant and Class Counsel in 
writing and specify the eligibility and/or entitlement criteria that the Claimant failed to 
satisfy. The Claims Adjudicator or Claims Adjudicator shall provide a one-time twenty 
(20) calendar day remedial period, which commences from the date of mailing of the 
written notification by the Claims Adjudicator, in which a Claimant can rectify any errors 
in the Claim Form. 
10.20 The Claims Adjudicator shall review all timely and complete Claim Forms 
and any responses submitted by Novartis pursuant to Paragraph 10.16 to determine: 
(1) whether each Eligible Claimant has substantiated her claim for a compensatory award 
and is thus entitled to payment from the Maximum Class Award for Compensatory 
Damages calculated pursuant to Paragraphs 10.1(iv)(a) and (b), and (2) which, if any, such 
Eligible Claimants are entitled to an increased compensatory award pursuant to Paragraphs 
10.1(iv)(c) and 10.15, and the amount of any increase to be awarded from the Maximum 
Class Award for Compensatory Damages. 
10.21 The Claims Adjudicator shall complete its review and issue a final 
determination as to which, if any, Eligible Claimants are entitled to a compensatory award, 
and the amount to which each such Eligible Claimant is entitled, within one hundred and 
twenty (120) calendar days of the deadline for submission of Claim Forms or, if applicable, 
the extended deadline for submission of Claim Forms pursuant to Paragraph 10.18. Eligible 
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Claimants determined to be entitled to a compensatory award will receive payment pursuant 
to the monetary distribution procedure described below in Section X.J. 
10.22 Decisions by the Claims Adjudicator granting or denying claims for 
compensatory awards, as well as determinations of the amount of increase, if any, in 
compensatory awards pursuant to Paragraphs 10.1(iv)(c) and 10.15, will be final and non-
appealable. 
10.23 If the Claims Adjudicator rejects a Claim Form as not meeting the terms 
or provisions of the Settlement Agreement, after a one-time opportunity to remedy pursuant 
to Paragraph 10.19 has been afforded, or rejects a claim for a compensatory award as 
unsubstantiated, the Claims Adjudicator shall so notify the Claimant in writing and specify 
the eligibility and/or entitlement criteria that the Claimant failed to satisfy. 
G. Objections. 
10.24 Proposed Settlement Class Member objections to this Settlement 
Agreement must be submitted in writing, and must include a detailed description of the 
basis of the objection. 
10.25 Objections must be filed with the Court, with copies served on the Claims 
Administrator, Claims Adjudicator, Class Counsel and Counsel for Novartis, within forty-
five (45) calendar days after the Notice is mailed by the Claims Administrator. Proposed 
Settlement Class Members who fail to make objections in the manner specified above shall 
be deemed to have waived any objections and shall be foreclosed from making any 
objection (whether by appeal or otherwise) to the Settlement Agreement. 
10.26 No one may appear at the Final Fairness Hearing for the purpose of 
objecting to the Settlement Agreement without first having filed and served her objection(s) 
in writing within forty-five (45) calendar days after the Notice was mailed to Proposed 
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Settlement Class Members. Any lawyer representing a Proposed Settlement Class Member 
for the purpose of making objections must also file a Notice of Appearance with the Court 
by the objection deadline and must also serve copies by mail to Counsel for the Parties by 
the objection deadline set forth above. 
10.27 An objector may withdraw her objection at any time. 
H. Exclusions. 
10.28 Proposed Settlement Class Members may exclude themselves, or opt out, 
of the Settlement. Any Proposed Settlement Class Member who wants to opt out of the 
Settlement Class may file a timely request for exclusion pursuant to the provisions 
described in the Notice of Class Action Settlement. Such written request for exclusion must 
contain the name, address and telephone number of the person requesting exclusion. The 
opt-out must be personally signed by the Proposed Settlement Class Member who seeks to 
opt out. No opt-out request may be made on behalf of a group of Proposed Settlement Class 
Members. The request for exclusion must contain the statements described in the Notice of 
Class Action Settlement, and must be sent by mail or courier to the Claims Administrator so 
that it is actually postmarked (or received, if by courier) within thirty-five (35) calendar 
days after Notice was mailed by the Claims Administrator. The postmark date of the 
mailing envelope shall be the exclusive means used to determine whether a request mailed 
for exclusion (opt-out) has been timely submitted. Any person who timely submits such a 
request for exclusion shall be barred from participation in the Settlement, and shall receive 
no benefit from the Settlement. The Claims Administrator shall provide Class Counsel and 
Counsel for Novartis with a copy of all opt-out statements on a weekly basis. 
10.29 Class Counsel shall file with the Court all timely opt-out statements. The 
Court must approve and order the exclusion of Proposed Settlement Class Members seeking 
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to opt out from the injunctive relief portion of this Agreement in order for the requested 
exclusion to be effective. Individuals who file and serve a timely opt-out statement are not 
entitled to any monetary award under this Settlement Agreement. 
I. Determination —Final and Binding. 
10.30 All final determinations of the Claims Adjudicator shall be binding and 
non-appealable. 
10.31 The Claims Administrator and Claims Adjudicator shall keep the Claim 
Forms and its determinations confidential and shall not disclose the number and/or identity 
of the Eligible Claimants or the value of their claims except as provided for in this 
Settlement Agreement. 
J. Class Monetary Distribution Procedure. 
10.32 No later than ten (10) calendar days after the deadline for completion of 
the entire claims process described in Paragraph 10.21, the Claims Administrator shall 
provide Novartis and Class Counsel with (1) a list of names and social security numbers of 
Settlement Class Members to whom a backpay award is due and the amount each 
Settlement Class Member is to be paid under Paragraph 10.1(iii), and (2) a list of the names 
and social security numbers of the Settlement Class Members to whom a compensatory 
award is due and the amount each Settlement Class Member is to be paid under Paragraph 
10.1(iv). 
10.33 No later than forty (40) calendar days after the deadline for completion of 
the claims determination process described in Paragraph 10.21, the Claims Administrator 
shall cause to be mailed, via certified mail, return receipt requested, payment checks and 
any appropriate 1099 forms to the Settlement Class Members to whom a payment is due. 
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10.34 If a Settlement Class Member to whom a payment is due is deceased at the 
time of such distribution hereunder, the amount payable to such deceased Settlement Class 
Member shall be paid to her estate, provided that the estate provides an appropriate 
certification to the Claims Administrator. 
10.35 The face of each check sent pursuant to Paragraphs 10.32 to 10.34 to 
Settlement Class Members to whom a payment is due shall clearly state that the check must 
be cashed within one (1) year. All payment checks distributed by the Claims Administrator 
must be accompanied by a cover letter stating words in bold to the effect that “the check 
must be cashed within one (1) year or it will become void.” The back of each check will 
contain a legend stating: “By negotiating this check and accepting payment I agree that I 
have waived and released the Released Parties from all Released Claims as defined in the 
Settlement Agreement and in the Notice in this matter. This Release is effective as of the 
Effective Date.” 
XI. NOVARTIS’S RIGHT TO WITHDRAW OR MODIFY THE 
AGREEMENT 
11.1 If a total of ten percent (10%) or more Proposed Settlement Class 
Members submit timely and complete requests for exclusion, Novartis shall have the 
absolute right, in its sole discretion and notwithstanding any other provisions of this 
Agreement, but subject to all the provisions and time limits of this Section, to withdraw in 
writing from this Agreement, or to modify this Agreement through further negotiations with 
Class Counsel. If Novartis does withdraw in conformity with the provisions and time limits 
of this Section, the Agreement will be null and void for all purposes and may not be used or 
introduced in further litigation except to determine whether Novartis is entitled to withdraw 
from the Agreement and has validly done so. 
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11.2 The Claims Administrator shall each calendar week notify Counsel for 
Novartis and Class Counsel by fax or e-mail of the number of individuals who have to that 
date submitted timely and complete requests for exclusion, and at the same time shall send 
to said Counsel by fax, e-mail or by overnight delivery copies of all the timely and complete 
requests for exclusion which Class Counsel has received. Novartis shall have thirty (30) 
calendar days after the expiration of all Proposed Settlement Class Members’ deadlines in 
Section X.E above to withdraw from (or modify through negotiation) this Agreement on the 
basis that a total of ten percent (10%) or more Proposed Settlement Class Members have 
submitted timely and complete requests for exclusion. 
XII. DUTIES OF THE PARTIES PRIOR TO COURT APPROVAL 
12.1 Promptly upon execution of this Agreement, but by no later than ten (10) 
calendar days thereafter, Class Counsel shall apply to the Court for the entry of an order 
(the “Preliminary Approval Order”): 
(i) Preliminarily approving the Agreement, as well as the payment of 
attorneys’ fees, costs, and Service Award Payments described in 
this Agreement; 
(ii) Approving as to form and content the proposed Notice of Class 
Action Settlement; 
(iii) Approving as to form and content the proposed Claim Form; 
(iv) Directing the mailing of the Notice and Claim Form by first class 
mail to the Proposed Settlement Class Members; 
(v) Certifying the Settlement Class; and 
(vi) Scheduling a Final Fairness Hearing as soon as practicable on the 
question of whether the proposed settlement should be finally 
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approved as fair, reasonable and adequate as to the Settlement 
Class Members. 
12.2 In applying for the entry of the Preliminary Approval Order, Class 
Counsel and Counsel for Novartis will jointly submit to the Court for its approval this 
Settlement Agreement, exhibits, and supporting papers, which shall describe the terms of 
this settlement and will include proposed forms of all notices and other documents as 
attached hereto necessary to implement the Settlement Agreement. 
12.3 In computing any period of time prescribed or allowed by this Settlement 
Agreement, unless otherwise stated, such computation or calculation shall be made 
consistent with Federal Rule of Civil Procedure 6(a). 
XIII. DUTIES OF THE PARTIES FOLLOWING FINAL COURT APPROVAL 
13.1 In connection with the Final Approval by the Court of the Agreement, 
Class Counsel and Counsel for Defendant will submit a proposed final order and judgment: 
(i) Granting final approval to the Agreement, adjudging the terms 
thereof to be fair, reasonable and adequate, and directing consummation of its terms and 
provisions; 
(ii) Dismissing the Civil Action with prejudice and permanently 
barring all members of the Settlement Class including the Class Representatives from 
prosecuting against any Released Parties any of the Released Claims; and 
(iii) Ordering that all materials containing Confidential or Highly 
Confidential Information pursuant to the Protective Order entered in the Civil Action 
shall be returned to the producing party or destroyed by the party to whom those 
materials were produced within one-hundred eighty (180) calendar days after the 
Effective Date, with the exception that the Parties may retain copies of their work 
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product; copies of all filed documents (whether or not filed under seal or submitted to the 
court without being officially filed); and materials necessary to oversee compliance with 
this Agreement, except that all documents and materials designated Highly Confidential 
shall be returned to Novartis or Novartis’s Counsel, who shall retain and maintain that 
information in the form in which it is returned during the term of this Settlement 
Agreement. 
XIV. PARTIES’ AUTHORITY 
14.1 The signatories hereby represent that they are fully authorized to enter into 
this Agreement and to bind the Parties and the Proposed Settlement Class Members to the 
terms and conditions hereof. 
14.2 All of the Parties acknowledge that through this Settlement Agreement 
and its attachments, they and the Proposed Settlement Class Members are being advised that 
they may consult an attorney regarding their participation in this Agreement, and the Parties 
acknowledge that they in fact have been represented by competent, experienced Counsel 
throughout all negotiations that preceded the execution of this Agreement, and this 
Agreement is made with the consent and advice of Counsel who have jointly prepared this 
Agreement. 
14.3 All of the Parties and Proposed Settlement Class Members acknowledge 
that they are participating voluntarily and knowingly in exchange for the consideration 
described herein. The Parties and Proposed Settlement Class Members further acknowledge 




15.1 Unless otherwise specifically provided herein, all notices, demands or 
other communications given hereunder shall be in writing and shall be deemed to have been 
duly given as of the third business day after mailing by United States registered or certified 
mail, return receipt requested, addressed as follows: 
To the Class Representatives or to any Proposed Settlement Class Member: 
SANFORD WITTELS & HEISLER, LLP 
David Sanford, Esq. 
Katherine Kimpel, Esq. 
1666 Connecticut Avenue, Suite 310 
Washington, D.C. 20009 
To the Defendant: 
CRAVATH, SWAINE & MOORE LLP 
Evan R. Chesler, Esq. 
Darin P. McAtee, Esq. 
825 Eighth Avenue 
New York, NY 10019 
XVI. CONFIDENTIALITY AND PUBLIC COMMENT 
16.1 Nothing in this Agreement shall be construed to permit anyone (including 
Class Counsel or any consultant pursuant to this Agreement) to make public Novartis’s 
confidential personnel information. Nor will any provision require Novartis to make public 
such information. 
16.2 Other than necessary disclosures made to the Court, the content of the 
Parties’ settlement negotiations shall be held confidential by Counsel for Novartis, Novartis, 
Class Counsel and the Class Representatives. 
16.3 Counsel for Novartis, Novartis, Class Counsel, and the Class 
Representatives shall not disclose to any third party, including but not limited to 
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communications on the internet (e.g., postings on personal or public websites such as social 
networking sites and blogs) or by means of any electronic or print media, any information 
about any aspect of the settlement, including the content of the settlement negotiations, 
subject to the following exceptions: 
(i) Nothing in the above shall limit Class Counsel’s right to 
communicate with Proposed Settlement Class Members. Class Counsel may 
communicate about the content of the settlement negotiations with Proposed Settlement 
Class Members for purposes of implementing, administering and enforcing the 
Settlement, and Class Counsel may respond to inquiries they respectively receive from 
Proposed Settlement Class Members. In addition, the Class Representatives may 
communicate about the content of the settlement negotiations with Proposed Settlement 
Class Members for purposes of implementing, administering and enforcing the 
Settlement as provided herein; 
(ii) Proposed Settlement Class Members and Class Representatives 
may share the details of their receipt of monetary relief for compensatory damages and 
backpay with their tax advisor for the purpose of preparing income tax returns; 
(iii) Novartis may communicate with those persons, including Novartis 
employees, necessary for the administration, implementation, and enforcement of the 
Settlement, and may inform its employees of the Settlement; 
(iv) Novartis may make public disclosures in accordance with 
securities law or for other regulatory purposes and may communicate with those persons 
necessary for the preparation and dissemination of such public disclosures; and 
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(v) The Parties will agree upon language for a joint press release 
(attached hereto as Exhibit C) announcing the Settlement upon an agreed date not before 
the filing of the request for Preliminary Approval with the Court; neither Party will 
separately issue its own press release or separately communicate with members of the 
press about any aspect of the Settlement at any time. 
16.4 Class Counsel agrees to use the contact information for Proposed 
Settlement Class Members that is provided to it by the Claims Administrator and Counsel 
for Novartis solely for purposes of communicating regarding this action and implementing 
this Agreement and for no other purpose, at any time, or for any reason. 
16.5 Any Settlement Class Member that receives a compensatory award agrees 
to be bound by a confidentiality provision separate and apart from any other confidentiality 
provision in this agreement. Specifically, she shall agree and promise that she has not 
communicated or disclosed, and will not hereafter communicate or disclose in the future, 
the sum of any payment made to her under this Agreement to any persons other than 
members of her immediate family, her present attorneys, accountants and/or tax or financial 
consultants, state and federal tax authorities or other persons as may be required by law 
provided, however, that any such person or entity to whom disclosure is made shall be 
instructed in advance by each Claimant that the information is strictly confidential pursuant 
to this Agreement. For all other purposes, Claimant shall indicate only that her lawsuit has 
been “resolved.” 
XVII. MODIFICATION 
17.1 This Agreement and its attachments may not be terminated or 
substantively changed, altered or modified, except as approved by the Court. 
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XVIII. ENTIRE AGREEMENT 
18.1 This Agreement and its exhibits and attachments constitute the entire 
agreement between the Parties and Proposed Settlement Class Members concerning the 
subject matter hereof. No extrinsic oral or written representations or terms shall modify, 
vary or contradict the terms of this Agreement. In the event of any conflict between this 
Agreement and any other Settlement-related document, the Parties and Proposed Settlement 
Class Members intend that this Agreement shall be controlling. 
XIX. INTERPRETATION 
19.1 This Agreement shall be construed as a whole according to its fair 
meaning and intent, and not strictly for or against any party, regardless of who drafted or 
who was principally responsible for drafting this Agreement or any specific term or 
condition thereof. 
XX. CHOICE OF LAW AND JURISDICTION 
20.1 This Agreement and the exhibits thereto shall be considered to have been 
negotiated, executed and delivered, and to be wholly performed, in the State of New York, 
and the rights and obligations of the Parties to this Agreement shall be subject to, governed 
by, construed, enforced, and administered in accordance with the laws of the State of New 
York, without giving effect to that State’s choice-of-law principles. 
20.2 The Court, and any appellate court from which appeals of the Court’s 
decisions may properly be brought, shall retain jurisdiction of the implementation and 
enforcement of the terms of this Agreement, and all Parties hereto and their counsel shall 
submit to the exclusive jurisdiction of the Court for purposes of implementing and 
enforcing the Settlement embodied in this Agreement. 
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XXI. COUNTERPARTS 
21.1 This Agreement may be executed in counterparts, and when each party has 
signed and delivered at least one such counterpart, each counterpart shall be deemed an 
original, and, when taken together with other signed counterparts, shall constitute one 
Agreement, which shall be binding upon and effective as to all Parties and Proposed 
Settlement Class Members. 
XXII. VOIDING THE AGREEMENT 
22.1 In the event this Agreement, or any amended version agreed upon by the 
Parties, does not obtain judicial approval for any reason, this Agreement shall be null and 
void in its entirety, unless expressly agreed in writing by all Parties. In the event this 
Agreement becomes null and void for any reason, Novartis, Counsel for Novartis, the Class 
Representatives, and Class Counsel agree that they shall from that date forward keep strictly 
confidential the terms of the Agreement, the existence of the Agreement, any information 
concerning the Agreement, or any of the discussions and or negotiations regarding the 
Agreement. 
IN WITNESS WHEREOF, the undersigned have duly executed this Agreement 
as of the date indicated below: 
Dated: July 14, 2010 SANFORD WITTELS & HEISLER, LLP 
David Sanford, Esq. 
Katherine Kimpel, Esq. 
Steven Wittels, Esq. 
Grant Morris, Esq. Of Counsel 
1666 Connecticut Ave., NW, Suite 310 
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Washington, D.C. 20009 
Tel. (202) 742-7780 
Fax (202) 742-7776 
Dated: July 14,2010 
Counsel for Plaintiffs and the Settlement Class 
CRAVATH, SWAINE & MOOREjLLP 
Evan R. Chesler, Esq. 
Darin P. McAtee, Esq. 
825 Eighth Avenue 
New York, NY 10019 
Tel.: (212) 474-1243 
Fax:(212)474-3700 
Counsel for Defendant Novartis Pharmaceuticals 
Corporation 
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UNITED STATES DISTRICT COURT 
SOUTHERN DISTRICT OF NEW YORK 
Velez, et al. v. Novartis Pharmaceuticals 
Corporation 
Class Action 
Civil Action No. 04 Civ. 9194 (CM) 
NOTICE OF PENDENCY OF CLASS ACTION 
PROPOSED SETTLEMENT AND SETTLEMENT HEARING 
TO: All women who are currently holding, or have held, a SALES-RELATED 
POSITION with NOVARTIS PHARMACEUTICALS CORPORATION 
(“Novartis”) from JULY 15, 2002 through [PRELIMINARY APPROVAL DATE, 
i.e. July 14, 2010] (“The Settlement Class”). 
This Notice is being sent to you, by order of the United States District Court for the 
Southern District of New York (the “Court”). It describes a proposed settlement (the 
“Settlement”) of a gender discrimination class action against Novartis Pharmaceuticals 
Corporation (the “Civil Action”) and your right to receive money from this Settlement. 
PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. 
YOUR RIGHTS WILL BE AFFECTED BY THE LEGAL PROCEEDINGS IN THIS 
LITIGATION. 
YOU ARE ENTITLED TO MONEY FROM THIS SETTLEMENT. 
Summary of Settlement: 
On November 19, 2004, the Class Representatives filed this lawsuit, on behalf of 
themselves and a class of current and former female sales force employees of Novartis 
Pharmaceuticals Corporation (“Novartis” or “NPC”), claiming that Novartis discriminated 
against women in three main respects: (1) pay; (2) promotion to management; and (3) on the 
basis of pregnancy. The Class Representatives litigated this gender discrimination case against 
Novartis for nearly six years until the parties reached a final settlement agreement in July 2010. 
The Settlement makes available settlement benefits of up to $175,000,000 ($175 
million) in monetary and non-monetary relief, comprised of a cash payment of up to 
$152,500,000 ($152.5 million) (the “Settlement Fund”) and of changes to Novartis’s 
employment practices valued at $22,500,000 ($22.5 million), as described in this Notice. As 
a former or current female sales force employee, you are eligible to participate in the 
settlement benefits. 
Specifically, this Notice is being sent to all women who are currently holding, or have 
held, a sales-related position of Sales Representatives, Sales Consultants, Senior Sales 
Consultants, Executive Sales Consultants, Sales Associates, Sales Specialists, Senior Sales 
Specialists or District Managers I with Novartis Pharmaceuticals Corporation (together the 
“Proposed Settlement Class Members” or “Settlement Class Members” and each a “Proposed 
Settlement Class Member” or “Settlement Class Member”), excluding individuals who entered 
into individual releases as part of individual agreements with Novartis from the start of the class 
period, July 15, 2002, through the date of preliminary approval (“Preliminary Approval Date”) 
that did not carve out an exception for this Civil Action. 
The Court in charge of this case is the United States District Court for the Southern 
District of New York, and the case is known as Velez, et al. v. Novartis Pharmaceuticals 
Corporation. This case is assigned to United States District Judge Colleen McMahon. The 
Court has preliminarily approved the Settlement and wishes to inform you of the general terms 
of the Settlement and what actions you need to take to participate in the benefits provided by the 
Settlement. 
The Court will be holding a hearing to consider whether the Settlement is fair, 
reasonable, and adequate, and to decide whether to give final approval to this Settlement. The 
Final Fairness Hearing will be held on November 19, 2010 at [] a.m., before the Honorable 
Colleen McMahon, United States District Judge, Southern District of New York, 500 Pearl 
Street, Courtroom 14C, New York, New York 10007. If the Court approves the Settlement, the 
Court’s judgment will be final and binding, and payments will be made after the completion of 
all claims processing. 
You may attend this hearing if you wish, but you are not required to appear at the 
hearing. If you are a Class Member, you will be represented by Class Counsel at no cost to you. 
If you wish to remain a Class Member and receive a share of the backpay monetary 
relief, you do not have to do anything in response to this Notice. 
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However, if you wish to receive additional money in the form of compensatory 
damages (for pain and suffering), this Notice will describe the procedures to do so. 
Or, if you wish to opt out from the settlement or object to it, this Notice will describe 
those procedures. 
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PURPOSE OF THIS NOTICE 
This Notice explains the Civil Action, the Settlement, the certification by the Court of the 
Settlement Class, your legal rights, what benefits are available, who is eligible for them, and how 
to get them. 
Your interests have been represented in the Civil Action by Class Counsel, Sanford 
Wittels & Heisler, LLP. This firm represents the interests of you and all Proposed Settlement 
Class Members. If you have questions regarding this Notice or your rights in this Settlement, 
you may contact Class Counsel at novartissettlement@swhlegal.com or visit 
www.swhlegal.com. 
If you want to be represented by your own lawyer (other than Class Counsel), you may 
hire one at your own expense. 
LITIGATION BACKGROUND 
On November 19, 2004, the Class Representatives filed a Class Action Complaint against 
Novartis in the United States District Court for the Southern District of New York, on behalf of 
themselves and a nationwide class of female sales force employees of Novartis under Title VII of 
the Civil Rights Act of 1964, 42 U.S.C. § 2000(e) et seq. The Fourth Amended Complaint was 
filed on March 13, 2006. 
On January 16, 2007, the Class Representatives filed their Motion to Certify a Class, and 
on July 31, 2007, the Court granted the certification motion. On August 16, 2007, the Court 
issued an Amended Opinion and Order certifying the proposed class, and issued notice of court 
approval of class certification on December 7, 2007. The notice was addressed to all women 
who were employed in certain sales-related positions with Novartis in the period between July 
15, 2002, and November 30, 2007. A jury trial commenced on April 7, 2010. 
The jury delivered a verdict on behalf of Plaintiffs on all counts and awarded 
compensatory and punitive damages. The trial concluded on May 19, 2010, with equitable relief 
and non-monetary relief to be ordered by the Court at a later date. 
In order to secure certain, prompt and extensive relief for the Proposed Settlement Class 
and to avoid the risk of future litigation and appeals, the Parties engaged in vigorous settlement 
negotiations. In July 2010, the Parties reached an agreement providing for the settlement of the 
class action and executed a Settlement Agreement (the “Agreement” or “Settlement 
Agreement”). The Parties agree that the Settlement is fair, reasonable and adequate and that it 
serves the best interest of the Proposed Settlement Class based on all the facts and circumstances. 
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CLASS DEFINITION – YOU ARE A MEMBER OF THIS CLASS 
You are a member of the Settlement Class if you fit within this definition: 
All women who are currently holding, or have held, a sales-related position of Sales 
Representatives, Sales Consultants, Senior Sales Consultants, Executive Sales 
Consultants, Sales Associates, Sales Specialists, Senior Sales Specialists or District 
Managers I with Novartis Pharmaceuticals Corporation, from the start of the class period, 
July 15, 2002, through [Preliminary Approval Date]. You are excluded if you entered 
into individual releases as part of individual agreements with Novartis up to the 
Preliminary Approval Date that did not carve out an exception for this Civil Action. 
You have received this Notice because Novartis’s records reflect that you are a female and were 
employed by Novartis between July 15, 2002 and [Preliminary Approval Date, i.e. July 14, 
2010], subject to the definition above, and that you are therefore a Settlement Class Member. 
Your rights may be affected by the legal proceedings in this action. 
DISCUSSION OF SETTLEMENT TERMS 
Under the terms of the Settlement, Novartis has agreed to pay a total amount of up to 
$175,000,000 ($175 million) in monetary and non-monetary relief, comprised of a cash payment 
of up to $152,500,000 ($152.5 million) (the “Settlement Fund”) and of changes to Novartis’s 
employment practices (described below) valued at $22,500,000 ($22.5 million). 
Both parties agree that the Settlement – under all the facts and circumstances – 
constitutes fair, adequate, and reasonable consideration for the settlement of all employment 
discrimination claims that were raised or could have been raised by the Named Plaintiffs or any 
member of the Proposed Settlement Class in the Civil Action, whether individually or as a class. 
How Will My Settlement Award Be Calculated? 
Settlement Class Members will be eligible to receive up to two monetary awards, in 
settlement of their claims for (1) backpay or lost wages, and (2) compensatory damages. 
(1) Monetary awards for backpay or lost wages will be calculated based on the number of 
months you worked at Novartis during the Settlement Class Period and will be distributed 
out of a “Class Award for Backpay” of approximately $60,000,000 ($60 million). You 
do not need to do anything to receive your backpay award. 
A fixed monthly amount for backpay (“Backpay Monthly Amount”) will be calculated by 
dividing the “Class Award for Backpay” by the total months worked by all class 
members in jobs included within the class definition during the Settlement Class Period. 
That monthly amount will then be multiplied by the number of months you worked in a 
class-eligible job during the Settlement Class Period. Your backpay award is subject to 
all applicable tax withholdings (which includes the employer’s share of federal and state 
6 
payroll taxes). Applicable withholdings and deductions will be made prior to the mailing 
of your backpay award, and you will receive IRS Forms W-2 for the amounts reportable 
on each Form. 
(2) Monetary awards for compensatory damages will be calculated based on the number of 
months you worked at Novartis during the Settlement Class Period and will be distributed 
out of the “Maximum Class Award for Compensatory Damages” of approximately 
$40,000,000 ($40 million). To be eligible for a compensatory damage award, you 
must submit a Claim Form – payment of compensatory awards is NOT automatic. 
A fixed monthly amount for compensatory damages (“Compensatory Monthly Amount”) 
will be calculated by dividing the “Maximum Class Award for Compensatory Damages” 
by the total months worked by all Settlement Class Members in class-eligible jobs during 
the Settlement Class Period. That monthly amount will then be multiplied by the number 
of months you worked in a class-eligible job during the Settlement Class Period. 
a. Each Settlement Class Member who seeks to receive an award for 
compensatory damages MUST COMPLETE a Claim Form, which is 
attached hereto as Exhibit B, and submit it by December 12, 2010. 
b. If you believe that the pain and suffering you experienced as a result of 
Novartis’s discriminatory treatment was particularly severe, you may choose 
to complete an additional form (the “Rider”) which may entitle you to an 
increase in your compensatory damages up to $300,000 total. This extra 
form requires you to identify a “Medical Professional” (defined as a 
physician or clinical psychologist) who treated you at any time during the 
period July 15, 2002 to [Preliminary Approval Date, i.e. July 14, 2010] for 
pain and suffering resulting from gender discrimination you experienced 
while working in a class-eligible job. 
(i) To be eligible for an increase over the standard compensatory award, 
you will need to declare on the Rider under penalties of perjury (but 
without a notarized requirement) that you received medical treatment 
from a Medical Professional at any time during the relevant time 
period for the physical and/or emotional pain and suffering caused by 
the gender discrimination at Novartis which you allege in your Claim 
Form. You will also need to provide a reasonable explanation of 
your medical treatment, and will need to attach a declaration from 
your Medical Professional. 
(ii) Your treating Medical Professional will need to declare in writing and 
under penalties of perjury (but without a notarized requirement): 
(1) that he or she provided medical treatment to you during the 
relevant time period for physical and/or emotional pain and suffering 
resulting from gender discrimination you experienced while working 
in a class-eligible job, and (2) describing the nature of the treatment 
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provided to you. You must attach your Medical Professional’s 
written declaration to your Rider. 
(iii) No one at Novartis and none of Novartis’s attorneys will have access 
to any of the information that you or your Medical Professional 
provide on the Rider. 
(iv) If the Court approves this Settlement, the Rider and instructions for 
completion will be provided to you in the separate mailing that also 
provides information on the basic compensatory award Claim Form 
detailed above. 
Will I Face Retaliation for Participation? 
No. 
If you are a former employee, Novartis cannot and will not inform anyone as to whether 
or not (a) you are a member of the Proposed Settlement Class, (b) you have participated in the 
settlement in any way, or (c) you have received compensation as a part of the Settlement. 
If you are a current employee, Novartis cannot and will not hold against you (a) the fact 
that you are a member of the Proposed Settlement class, (b) whether you participate in the 
settlement in any way, or (c) whether you receive compensation as a part of the Settlement. In 
addition, Novartis cannot and will not credit you or give you any sort of benefit if you choose to 
opt-out of the Settlement. As a term of this Agreement, Novartis has limited the individuals who 
will administer the Settlement, and Field Management will not be involved in nor have access to 
information about the backpay award process or the compensatory settlement claims process. 
Will the Women Who Litigated This Case Receive a Service Payment? 
Class Counsel will apply for service payments of $125,000 each for the Class 
Representatives and the other women who testified at trial to compensate them for the time and 
effort they devoted to representing the Class in this case, including the time they spent consulting 
with Class Counsel about the case. Class Counsel will seek $150,000 for Amy Velez, the 
original Class Representative, who started the case in 2004. 
In addition, Class Counsel will seek $25,000 for the women who provided extensive 
discovery – including giving a sworn deposition – that required significant time and effort on 
their part. These payments come from the Settlement Fund and do not reduce the amounts 
detailed above in the “Backpay Settlement Fund” or the “Maximum Class Award for 
Compensatory Damages” from which your recovery will be drawn. 
What Does Novartis Have to Do Under the Settlement? 
Under the Settlement, Novartis agrees to make changes to its policies and practices 
regarding complaints of discrimination as well as compensation, performance evaluation and 
promotion of its field force employees. These changes are valued at approximately $22,500,000 
($22.5 million). 
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Novartis has agreed to be bound by the Settlement for a three-year period. The overall 
objective of this Agreement is to ensure equal employment opportunities for women who work at 
Novartis. In order to do so, Novartis has agreed to many steps, including but not limited to the 
following: 
1. Novartis will prepare and circulate a sexual harassment policy that will cover 
inappropriate conduct by employees and physician customers and will make clear that 
Novartis does not tolerate inappropriate sexual behavior or comments by physician 
customers. Novartis will conduct annual training on this policy. 
2. Novartis will increase the size of its Employee Relations staff designated to respond 
to and investigate complaints of discrimination as well as its Human Resources 
Business Partner staff. 
3. Novartis will revise the policies and processes regarding its investigation into 
discrimination, including establishing a new “hotline” specific to Employee Relations 
complaints. Novartis will communicate to employees its policy that requires all 
employees to immediately report—to the BPO, Employee Relations Hotline, 
Alertline, his or her Supervisor, an officer of the Company, or a representative of 
Human Resources, Ethics and Compliance or Legal—all complaints of misconduct. 
Novartis will also communicate to employees its policy that requires managers or 
upper-level Novartis employees to immediately report—to the BPO, Employee 
Relations Hotline, AlertLine, his or her Supervisor, an officer of the Company, or a 
representative of Human Resources, Ethics and Compliance or Legal—all complaints 
of misconduct made by others, and that management may not exercise its discretion 
regarding whether or not to report such a complaint. 
4. Novartis has developed a formalized complaint investigation process, which it will 
continue to follow, including the practice that all investigative steps taken by the 
Employee Relations Group either be made in writing or documented after the fact. 
Novartis will further maintain an electronic database of any complaints and the 
disciplinary action taken (if any). 
5. With respect to its Performance Evaluation Process, Novartis will evaluate how to 
ensure that an employee’s leave of absence, including pregnancy leave, will not result 
in negative performance ratings for his/her manager, his/her counterparts in the 
territory and the employee in question, and will develop and issue specific guidance 
regarding implementation of the Values and Behaviors and Objective evaluation. 
6. Novartis will provide mandatory training for all managers regarding the performance 
evaluation process. 
7. Novartis will conduct an adverse impact analysis of performance ratings to determine 
if there are any significant gender disparities. Novartis will remedy, as soon as 
practicable, any gender-related problems affecting employees covered by this 
Agreement and evidenced in the analysis. 
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8. Novartis will conduct calibration sessions at the District Manager and second-line 
manager level for representatives (and at the second-line manager and Vice President 
level for District Managers) to ensure consistency in the evaluation of employees 
against a uniform understanding of the expectations. Human Resources will continue 
to play an active role in the calibration process. 
9. Novartis will conduct two different types of analysis on its current pay structure. 
First, Novartis will analyze the base salaries of its employees to check for any gender-
related discrepancies within the range of pay for each job. In case of any 
discrepancies versus range, Novartis will correct the problem within 18 months by 
making adjustments in base salaries based on these findings. Second, Novartis will 
perform an annual adverse impact analysis on annual rates of pay to identify any 
discrepancies based on gender and will make necessary adjustments based on these 
findings in the next merit cycle. 
10. Novartis will provide clear written materials regarding the pre-Management 
Development Program (“MDP”) checklist and the Management Development 
(“MD”) classes, how each stage progresses, what individuals need to do to move 
through each stage, and the frequency at which each of the MD classes are offered. 
Novartis has created and will continue to maintain a system that allows interested 
employees to self-register their interest in management electronically. 
11. Novartis will work with Luke Visconti, CEO from DiversityInc, and Joyce Dudley 
from Dudley Hamilton to work on the overall culture at Novartis and improve the 
Novartis work environment for all employees and report annually to the Novartis 
Executive Committee on recommendations and actions taken. 
RELEASE OF CLAIMS 
If the Court grants final approval of the Settlement, then all Settlement Class Members 
who do not opt out will fully, finally, and forever release employment claims covered by the 
Settlement Agreement against Novartis up to the Preliminary Approval Date. When claims are 
“released” it means that a person granting the release cannot sue Novartis for the same claims 
that are covered by the lawsuit as set forth below and in the Settlement Agreement. 
What this means for you is that you will not be able to bring a lawsuit in any form for 
anything related to any kind of employment discrimination at Novartis that happened before [the 
Preliminary Approval Date, i.e. July 14, 2010]. More specifically, you will be releasing any and 
all employment discrimination claims including, but not limited to, claims of alleged pay or 
promotion discrimination, sexual harassment claims, hostile work environment claims or benefits 
claims under Title VII, 42 U.S.C. § 1981a (“Section 1981a”), and any other applicable federal, 
state, or local statutes, common law, or regulation. This is true whether or not you are aware of 
those claims now. 
The release, however, will not include the Wage and Hour class action lawsuits now 
pending against Novartis. 
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This Release does not affect your rights, if any, to recovery in existing certified class 
actions in which you are currently a class member regarding non-discrimination related 
employment matters. It also does not affect your rights to any claims that might arise from any 
of Novartis’ actions or omissions occurring after the Preliminary Approval Date. 
The terms of the Release are set forth in Paragraph 2.20 and Section V of the Settlement 
Agreement. You may obtain a copy of the Settlement Agreement by contacting Class Counsel, 
as listed below, or you can view the Settlement Agreement in hard copy in the Office of the 
Clerk of the United States District Court, Southern District of New York, 500 Pearl Street, New 
York, NY 10007. 
THE SETTLEMENT PROCESS, FINAL FAIRNESS HEARING AND YOUR RIGHTS 
In order to decide whether to approve the proposed settlement, Judge McMahon will 
consider related papers and comments submitted by the Parties or others and will hold a hearing 
in open court. This Final Fairness Hearing will be held at [ T I M E ] on November 19, 2010 at 
the Southern District of New York, 500 Pearl Street, Courtroom 14C, New York, New 
York 10007. 
You do not need to appear at the hearing. However, you may attend and you may also 
enter an appearance in the case through your own attorney, if you so desire. This appearance 
must be filed with the Clerk’s Office and served on the Claims Administrator and Class Counsel 
no later than forty-five days after this Notice is postmarked. 
You also may decide to “opt out” or ask to be excluded from the Settlement. If you 
exclude yourself from the Class, you will not be legally bound by the Court’s judgments in this 
Civil Action but you also will not receive any money from this Class Action lawsuit – even if the 
proposed Settlement is approved. Of course, even if you exclude yourself from this lawsuit and 
you are currently employed by Novartis, any changes made to Novartis’s policies about the 
treatment of women would still apply to you. To ask to be excluded: 
(1) You must send a request for exclusion that contains your name, address and 
telephone number and must be personally signed by you. 
(2) The request for exclusion must contain the following language: “I understand that I 
am requesting to be excluded from the class monetary settlement and that I will 
receive no money from the settlement fund created under the Settlement Agreement 
entered into by Novartis Pharmaceuticals Corporation. I understand that if I am 
excluded from the class monetary settlement, I may bring a separate legal action 
seeking damages, but may receive nothing or less than what I would have received 
if I had filed a claim under the class monetary settlement procedure in this case. I 
also understand that I may not seek exclusion from the Class for programmatic 
relief and that I am bound by the programmatic relief provisions of the Settlement 
Agreement entered into by Novartis.” 
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(3) You must mail your request for exclusion postmarked by [], 2010 to [Claims 
Administrator Address]. 
You also may submit any objections to this proposed settlement in writing. For any such 
written objections to be considered, you must follow the steps detailed below: 
(1) You must file your written objection with the Clerk of the Court, United States 
District Court for the Southern District of New York, 500 Pearl Street, New York, 
New York 10007. Please do not send any comments directly to the Court or 
attempt to reach Judge McMahon in person. Your objection must be postmarked 
within 45 days after the postmark date of this Notice. 
(2) Copies of all such papers must be mailed and postmarked by the same date to both 
(i) the Claims Administrator at [INSERT ADDRESS] and (ii) Class Counsel at 
1666 Connecticut Ave. NW, Suite 310, Washington DC 20003. 
Any objection must detail the specific reason for the objection. 
THE LAWYERS REPRESENTING YOU AND THE CLASS 
As a Settlement Class Member, you are represented in this litigation by Class Counsel, as 
follows: 
David Sanford, Esq. 
Katherine Kimpel, Esq. 
Steven Wittels, Esq. 
Grant Morris, Esq. Of Counsel 
SANFORD WITTELS & HEISLER, L L P 
1666 Connecticut Ave. NW, Suite 310 




Unless you elect to exclude yourself from the Settlement, you will continue to be represented by 
Class Counsel in connection with implementation and monitoring of the Settlement throughout 
the three-year term of the Settlement at no cost to you. 
How Will The Lawyers Be Paid? 
In connection with the Settlement, the Court is expected to award Class Counsel 
reasonable attorneys’ fees and expenses out of the Settlement Fund. 
If you are a Settlement Class Member and receive an award from the Settlement 
Fund, you will not owe any fees or expenses to the lawyers who have represented you as a 
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part of the Settlement Class. Whatever the Court awards to Class Counsel in fees and expenses 
will be paid only if and after the Settlement has been approved by the Court. 
As is routine in class actions, Class Counsel will file a motion seeking court approval for 
an award of attorneys’ fees and expenses already incurred, as well as the fees and expenses that 
will be incurred during the three-year term of the Settlement. For more than six years, Class 
Counsel has vigorously litigated this case which involved extensive discovery including 
approximately 100 depositions, voluminous motion practice and appeals, and a 7-week trial. 
Class Counsel has litigated this case on behalf of you and the rest of the Settlement Class without 
receiving any compensation for their services or reimbursement of their out-of-pocket litigation 
expenses and has undertaken significant risks in pursuing this matter. They have done so with 
the understanding that, if they obtained a recovery for the Class, their expenses would be 
reimbursed and they would receive fees from the fund recovered. Accordingly, Class Counsel 
will request that the Court award them approximately $2,000,000 in expenses they have incurred, 
plus attorneys’ fees for the work performed and results achieved to date in an amount no greater 
than 25% of the proposed $152.5 million Settlement Fund. All fees and expenses include all 
future work Class Counsel will do associated with the next three years of monitoring the 
Settlement Agreement, responding to over 6,000 Class Members, and overseeing the claims 
process. 
PUBLIC COMMENT 
If you receive a compensatory damages award, you are bound by a specific 
confidentiality provision regarding the compensatory award. Specifically, this confidentiality 
provision requires a promise that you will not make a public comment regarding the amount of 
money you receive from Novartis as a part of this Settlement. You can discuss the amount you 
receive with members of your immediate family, your attorneys, accountants and/or tax or 
financial consultants, state and federal tax authorities or other persons as may be required by law. 
If and when you discuss your settlement with those individuals, you are expected to remind your 
listener in advance that the information is strictly confidential. If anyone other than the 
aforementioned individuals attempts to discuss the matter, you should indicate only that your 
lawsuit has been “resolved.” 
GETTING MORE INFORMATION 
If you have further questions or are still not sure whether you are included, you can get 
free help by contacting Class Counsel in this case at the contact information listed above. You 
may also contact the Claims Administrator at the contact information listed above. 
This Notice contains only an overview of the Settlement and related matters. For a more 
detailed statement of the matters involved in the proposed Settlement of this Action, you may 
examine the pleadings, the Agreement relating to the Settlement of the Action, and all other 
papers and documents filed with the Court in the Action, which may be inspected during normal 
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business hours at the United States District Court for the Southern District of New York, 500 
Pearl Street, New York, NY 10007. 
SHOULD YOU HAVE ANY QUESTIONS CONCERNING THIS NOTICE, THIS 
ACTION, THE PROPOSED SETTLEMENT OR THE FINAL FAIRNESS HEARING 
THEREON, YOU SHOULD DIRECT THEM TO CLASS COUNSEL IN THIS ACTION, 
AT THE ADDRESS SET FORTH ABOVE. PLEASE DO NOT CONTACT THE CLERK 
OF THE COURT. 
Dated: [], 2010 BY ORDER OF THE COURT 
UNITED STATES DISTRICT COURT 
SOUTHERN DISTRICT OF NEW YORK 
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CLAIM FORM 
Velez, et al. v. Novartis Pharmaceuticals Corp. 
Civil Action No. 1:04 Civ. 9194 (CM) 
IT IS IMPORTANT THAT YOU READ THE ATTACHED INSTRUCTIONS 
BEFORE YOU BEGIN FILLING OUT THIS CLAIM FORM 
TO BE VALID, YOUR CLAIM FORM MUST BE POSTMARKED 
ON OR BEFORE DECEMBER 12, 2010 
1. Full Name: 
Last First Middle 
2. Current Address: 
No. Street Name Apt. No. 
City State Zip Code 
3. Home Telephone Number: 
4. Cellular Telephone Number: 
5. E-Mail Address: 
6. Social Security Number: 
7. Date of Birth: 
8. To the best of your recollection, please provide the dates of your employment as an 
employee with Novartis Pharmaceuticals Corporation, or its predecessor company: 
/ / 
month/ year until month/year 
9. To the best of your knowledge or recollection, if you are able to do so, please provide 
the Novartis Pharmaceuticals Corporation Employee Number assigned to you during 
the dates of your employment with Novartis Pharmaceuticals Corporation, or its 
predecessor company: (if you cannot answer this question, it will not in any way be 
held against you) 
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10. Do you believe that, during the period July 15, 2002 to [Preliminary Approval Date], 
you were discriminated against on account of your gender in seeking a promotion, in 
the level of pay you received, or on account of pregnancy? 
Yes [ ] No [ ] 
11. If you answered “Yes” to Item 10, do you also contend that the gender 
discrimination you allege in this Claim Form caused you to experience physical 
and/or emotional pain and suffering? 
Yes [ ] No [ ] 
If you answered “Yes”, please provide an explanation in Items 12 and 13 below 
and sign the accompanying declaration. 
12. Provide in the lines below or as an attachment to this Claim Form a reasonably 
detailed explanation of the circumstances giving rise to your contention that the 
gender discrimination you allege in this Claim Form caused you to experience 
physical and/or emotional pain and suffering. 
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13. Provide in the lines below or as an attachment to this Claim Form a reasonably 
detailed explanation of the nature of the physical and/or emotional pain and 





I, , DECLARE UNDER 
PENALTIES OF PERJURY THAT THE INFORMATION AND FACTS I 
HAVE STATED IN THIS CLAIM FORM ARE TRUE AND CORRECT. 
Executed this day of , 2010. 
Signature 
Printed Name 
You MUST complete and SIGN your Claim Form in order for it to be considered. 
To be valid, your Claim Form must be postmarked on or before DECEMBER 12, 
2010. Late Claim Forms will not be considered. 
Your Completed and Signed Claim Form must be mailed to: 
Novartis Claims Administrator 
[Address] 
RETALIATION AGAINST A PERSON FOR 
FILING A CLAIM IS ILLEGAL 
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RIDER TO CLAIM FORM 
YOU DO NOT HAVE TO SUBMIT THIS RIDER TO RECEIVE A MONETARY 
AWARD FOR COMPENSATORY DAMAGES. YOU NEED TO COMPLETE 
THIS FORM ONLY IF YOU WANT TO SEEK ADDITIONAL 
COMPENSATORY DAMAGES BECAUSE THE HARM YOU SUFFERED 
REQUIRED YOU RECEIVE THE CARE OF A MEDICAL PROFESSIONAL. 
COMPLETION AND TIMELY SUBMISSION OF THIS RIDER MAY BE USED 
BY THE CLAIMS ADJUDICATOR ONLY TO DETERMINE THE AMOUNT OF 
YOUR COMPENSATORY DAMAGES AWARD. 
NOTE: All medical information will be kept strictly confidential. It will not be 
disclosed to Novartis Pharmaceuticals Corporation. It will be reviewed only by a 
Court appointed Claims Adjudicator to make determinations regarding your 
monetary award. 
1. Did you receive medical treatment from a “Medical Professional” (defined as a 
physician or clinical psychologist) during the period July 15, 2002 to 
[Preliminary Approval Date, i.e. July 14, 2010] for the physical and/or emotion 
pain and suffering you contend was caused by the gender discrimination you 
allege in the accompanying Claim Form? 
Yes [ ] No [ ] 
If you answered “Yes”, please provide an explanation in Item 2, attach 
to this Rider the declaration described in Item 3, and sign the accompanying 
declaration. 
2. Provide in the lines below or as an attachment to this Rider an explanation of the 
medical treatment you received from a Medical Professional during the period 
July 15, 2002 to [Preliminary Approval Date. i.e. July 14, 2010] for physical 
and/or emotion pain and suffering you contend was caused by the gender 
discrimination you allege in the accompanying Claim Form. 
Relevant information can include the name(s) and address(es) of each Medical 
Professional you have seen, the number of times you sought treatment, the 
duration and/or time period of any treatment, any diagnosis, and whether 
medication or any other treatment regimen was prescribed. 
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3. If you answered “Yes” to Item 1 above, attach to this Rider a declaration 
executed by the Medical Professional declaring under penalties of perjury 
(without a notarized requirement) that during the period July 15, 2002 to 
[Preliminary Approval Date. i.e. July 14, 2010], he or she treated you for 
physical and/or emotional pain and suffering resulting from gender 
discrimination you experienced while working in a class-eligible job, and 
describing the nature of the treatment that you were provided. 
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DECLARATION 
I, , DECLARE UNDER 
PENALTIES OF PERJURY THAT THE INFORMATION AND FACTS I 
HAVE STATED IN THIS RIDER ARE TRUE AND CORRECT. 
Executed this day of , 2010. 
Signature 
Printed Name 
You MUST complete and SIGN this Rider in order for it to be considered. 
To be valid, the Rider must be postmarked on or before DECEMBER 12, 2010. 
Late Riders will not be considered. 
Your Completed and Signed Rider must be mailed to: 
Novartis Claims Administrator 
[Address] 
RETALIATION AGAINST A PERSON FOR 
FILING A CLAIM IS ILLEGAL 
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CLAIM FORM INSTRUCTIONS 
Velez, et al. v. Novartis Pharmaceuticals Corp. 
Read Carefully Before You Complete the Attached Claim Form and Rider. 
1. You do not have to submit this Claim Form to receive a monetary award for backpay 
from the Class Award for Backpay portion of this settlement, described in the Notice 
of Class Action Settlement accompanying this Claim Form. This monetary amount 
will be sent to you automatically. 
2. To be eligible to file a claim in this case, you must be a member of the Settlement 
Class. 
3. For purposes of monetary relief, the Settlement Class consists of all women who are 
currently holding, or have held, a sales-related position of Sales Representatives, 
Sales Consultants, Senior Sales Consultants, Executive Sales Consultants, Sales 
Associates, Sales Specialists, Senior Sales Specialists or District Managers I with 
Novartis Pharmaceuticals Corporation from the start of the class period, July 15, 
2002, through [Preliminary Approval Date. i.e. July 14, 2010], excluding individuals 
who have entered into individual releases as part of individual agreements with 
Novartis up to the Preliminary Approval Date that not carve out an exception for this 
Civil Action. 
4. To be eligible to receive a monetary award for compensatory damages from the 
Maximum Class Award for Compensatory Damages portion of this settlement, 
described in the Notice of Class Action Settlement accompanying this Claim Form 
(“Eligible Claimant”), you must complete and submit this Claim Form to the Claims 
Administrator by the above deadline. 
5. To qualify as an Eligible Claimant, you must declare under penalties of perjury that 
you believe that during the period July 15, 2002 to [Preliminary Approval Date, i.e. 
July 14, 2010] you were discriminated against because of gender in seeking a 
promotion, in the level of pay received, and/or on account of pregnancy. 
6. To qualify as an Eligible Claimant, you must declare under penalties of perjury that 
you believe that, during the period July 15, 2002 to [Preliminary Approval Date, i.e. 
July 14, 2010], you suffered physical and/or emotional pain and suffering as a result 
of being discriminated against on account of your gender in seeking a promotion, in 
the level of pay you received, or on account of pregnancy. 
7. To qualify as an Eligible Claimant, you must provide a reasonably detailed 
explanation of the circumstances giving rise to your belief that you suffered pain and 
suffering as a result of being discriminated against on account of your gender in 
seeking a promotion, in the level of pay you received, or on account of pregnancy as 
well as an explanation of the nature of the pain and suffering that you believe you 
experienced. 
8. To qualify as an Eligible Claimant, you must satisfy each of the conditions for 
eligibility set forth in Section Paragraph 10.13 of the Agreement. 
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9. Each person who wishes to make a claim must submit her own Claim Form. 
10. You must answer all applicable questions and fill in all applicable blanks in Items 1 
through 13 on your Claim Form to participate in the claims process. Failure to 
complete that portion of your Claim Form will result in your claim being denied. 
11. You must sign the Claim Form. By doing so, you are declaring under penalties of 
perjury that the information on the form is true and correct. 
12. Completion and submission of the attached Rider is not required to receive a 
monetary award. If you complete the Rider and you also attach the declaration 
described in Item 3 of the Rider, that information may be used by the Claims 
Adjudicator to set the amount of your compensatory award. Completion of the 
attached Rider will allow the Claims Adjudicator to consider whether you should 
receive compensatory damages in excess of the amount you would receive based on 
the formula detailed in the Agreement. The Claims Adjudicator may award a total 
compensatory damages award of no more than $300,000. 
13. If you complete the attached Rider, you must also sign the accompanying declaration. 
By doing so, you are declaring under penalties of perjury that the information on the 
Rider is true and correct. In filling out your Claim Form, please print legibly or type. 
14. Your Claim Form, including the Rider, if applicable, must be completed in full and 
must be mailed and postmarked on or before December 12, 2010 or your claim will 
be denied. 
15. A designated representative at Novartis Pharmaceuticals Corporation (who is not part 
of Field Management or the Human Resources Department) will receive a copy of 
your Claim Form from the Claims Administrator and will be provided an opportunity 
to submit a written response. The representative will not reveal your identity or the 
fact that you are seeking compensatory damages with anyone in Field Management. 
In sum, the information contained in your Claims Form will be kept confidential by 
Novartis. In addition, the designated representative will not receive a copy of Rider 
A or any attachment thereto. This means that your claim will not result in an internal 
Novartis investigation regarding the substance of your claim. If you believe that you 
or anyone else is being subjected to ongoing discrimination, you must report the 
situation to the Novartis Business Practices Officer (“BPO”), the Employee Relations 
hotline, the Alertline, your Supervisor, an officer of Novartis Pharmaceuticals 
Corporation, or a representative of Human Resources, Ethics and Compliance or 
Legal for investigation and resolution. Novartis will not be able to investigate and 
resolve any ongoing problem unless you report it through one of these reporting 
methods. 
16. You do not need to nor will you be allowed to submit anything other than the Claim 
Form, and, if you choose, the Rider and attached declaration. Submission of a Claim 
Form is sufficient to make a claim for the formula compensatory damage award. 
Submission of the Rider and attached declaration is sufficient to make a claim for 
additional compensatory damages. The Claims Adjudicator’s decision on whether to 
award compensatory damages, and the amount, if any, of compensatory damages to 
award is final and non-appealable. 
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17. If you want further information about the settlement or have questions about these 
instructions or about how to complete the Claim Form, please e-mail Class Counsel 
at novartissettlement@swhlegal.com or call the Novartis Claims Administrator, at 1-
800-[ ]. Do not call the Court, the Clerk of Court, or Novartis 
Pharmaceuticals Corporation. 
18. Filing this Claim Form does not automatically guarantee that you will receive an 
award of monetary relief as part of the Settlement of the Velez Action. Your Claim 
Form will be subject to review and verification by the Claims Administrator and 
Claims Adjudicator. 
19. It is your responsibility to keep the Claims Administrator advised of any change in 
your address. If you do not keep the Claims Administrator advised of your current 
address, any monetary award to which you may be found entitled could be forfeited. 
Any change of address should be reported along with your complete name and 
signature, Social Security number, and former address. 
20. All communications to the Claims Administrator should be sent to: 
Novartis Claims Administrator 
[Address] 
21. You do not need to have an attorney to help you submit a Claim Form. However, 
you may contact Class Counsel at novartissettlement@swhlegal.com for any 
assistance or with any questions. In addition, if you wish to consult with your own 
attorney other than Class Counsel, you may do so at your own expense. 
22. Retaliation against a person for filing a claim is illegal and violates the Agreement. 
If you are a former employee, Novartis cannot and will not inform anyone whether 
you participate in the settlement in any way or whether you receive compensation as 
a part of the Settlement. If you are a current employee, Novartis cannot and will not 
hold against you or otherwise take into consideration whether you participate in the 
settlement in any way, or whether you receive compensation as a part of the 
Settlement. As a term of this Agreement, Novartis has limited the individuals who 
will administer the Settlement. 
23. Field Management will not be involved in nor have access to information about 
the backpay award process or the compensatory damages claims process. 
24. Claim Forms will be used only to administer the Settlement, and will not be 
admissible in a court or other legal proceeding for any other purpose. 
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Novartis International AG 
Novartis Global Communications 
CH-4002 Basel 
Switzerland 
http://www.novartis.com Sanford Wittels & Heisler, LLP 
http://www.swhlegal.com 
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG 
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary 
of Novartis AG, agree to resolve all gender discrimination claims 
associated with class action 
• Agreement reached between Novartis Pharmaceuticals Corporation (NPC) and 
Class Plaintiffs – company to make monetary payment of up to USD 152.5 million 
to eligible class members 
• As part of its commitment to fostering a diverse and inclusive workforce, NPC is 
implementing comprehensive programs designed to ensure that all members of 
its sales force are treated fairly 
Basel, July 14, 2010 –Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of 
Novartis AG, and Sanford Wittels & Heisler, LLP, Counsel to the Plaintiffs and the Class, 
have announced an amicable end to their litigation. Today the parties filed papers in the 
Southern District of New York memorializing a settlement agreement including up to 
USD 152.5 million in payments to eligible class members and NPC’s funding, over three 
years, of improvements to policies and programs valued at an estimated USD 22.5 
million. 
While the company maintains that the alleged behavior described during the trial is not 
systemic, NPC has agreed with the Plaintiffs to end the ongoing proceedings and make 
monetary payments to eligible class members for back-pay and compensatory damages 
in the amount of up to USD152.5 million. “While we believe that there was not systemic 
discrimination at NPC, the trial revealed that some of our associates had experiences 
influenced by managerial behavior inconsistent with our values” said Joe Jimenez, CEO 
of Novartis AG. “As a company we are now even more strongly resolved to ensure that 
all our employees act and behave in accordance with our corporate values. We aspire to 
be a leader in diversity and inclusion, and I am committed to implementing decisive 
measures to ensure that we act in accordance with our values.” 
“Novartis has agreed to a momentous settlement,” explained David Sanford, lead 
counsel for the Plaintiffs. “The terms of this agreement allow for full compensation of 
both former and current female field force employees, ensuring that every woman who 
worked at Novartis over the past eight years has been compensated fairly.” 
As part of the agreement and consistent with its philosophy to foster a diverse and 
inclusive workforce, NPC is implementing comprehensive programs designed to ensure 
1/4 
fair treatment of all members of the NPC sales force. The measures agreed to by the 
parties set high standards, and the company is committed to occupy a leadership 
position for gender equity in the industry. 
“In this settlement, Novartis establishes itself as a leader on issues for women in the 
workplace,” said Katherine Kimpel, co-lead counsel for the Plaintiffs. “In particular, NPC 
is committed to substantially revising its human resources policies, revamping its 
personnel management systems, and strengthening its commitment to ensuring gender 
equality in the workplace.” 
As part of the measures, NPC will enhance many of its ongoing commitments to all 
employees and will add additional programs and initiatives to further strengthen its 
commitment to a diverse and inclusive environment. For example: 
o NPC will revise its sexual harassment policy and training, making it even clearer 
that the company will not tolerate inappropriate behavior or comments from 
employees, customers or healthcare providers. 
o NPC will also further strengthen its complaint process to ensure employees can 
safely raise concerns and that those concerns will be addressed in a timely and 
thorough fashion; 
o NPC will retain an external specialist to conduct adverse impact analyses aimed 
at identifying and remedying, with recommendations from Class Counsel, 
unjustified gender disparities; 
o NPC will revise its performance management process to ensure it is fair to all 
employees. 
The full range of changes and improvements that NPC will be making are detailed in the 
settlement agreement filed with the Court. The agreement remains subject to final court 
approval. 
About Novartis 
Novartis provides healthcare solutions that address the evolving needs of patients and 
societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best 
meet these needs: innovative medicines, cost-saving generic pharmaceuticals, 
preventive vaccines, diagnostic tools and consumer health products. Novartis is the only 
company with leading positions in these areas. In 2009, the Group’s continuing 
operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion 
was invested in R&D activities throughout the Group. Headquartered in Basel, 
Switzerland, Novartis Group companies employ approximately 100,000 full-time-
equivalent associates and operate in more than 140 countries around the world. For 
more information, please visit http://www.novartis.com. 
About Class Counsel 
The Plaintiffs and the Class are represented by Sanford Wittels & Heisler, LLP. 
Sanford Wittels & Heisler is a law firm with offices in Washington, D.C., New York, 
and San Francisco that specializes in employment discrimination, wage and hour, 
consumer and complex corporate class action litigation and has represented 
thousands of individuals in some of the major class action cases in the United 
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States. The firm also represents individual clients in employment, employment 
discrimination, sexual harassment, whistleblower, public accommodations, 
commercial, medical malpractice, and personal injury matters. For more information, 
please visit http://www.swhlegal.com. 
# # # 
Sanford Wittels & Heisler, LLP Media Relations 
Jamie Moss of newsPRos: 
201-493-1027 
jamie@newsPRos.com 
For Sanford Wittels & Heisler multimedia content, please visit 
www.swhlegal.com/newsroom.html 
Novartis Media Relations 
Central media line: +41 61 324 2200 
Eric Althoff 
Novartis Global Media Relations 
+41 61 324 7999 (direct) 
+41 79 593 4202 (mobile) 
eric.althoff@novartis.com 
e-mail: media.relations@novartis.com 
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The foregoing release contains forward-looking statements that can be identified by 
terminology such as “committed”, “continues to”, or similar expressions, or by express or 
implied discussions regarding the potential outcome of any appeal which may be filed in 
the litigation which is the subject of this press release. Such forward-looking statements 
reflect the current views of the Company regarding future events, and involve known and 
unknown risks, uncertainties and other factors that may cause actual results to be 
materially different from any future results, performance or achievements expressed or 
implied by such statements. There can be no guarantee that NPC would be successful 
in any appeal which may be filed in the litigation which is the subject of this release. In 
particular, management’s expectations could be affected by, among other things, the 
inherent unpredictability of the litigation process, and other risks and factors referred to 
in Novartis AG’s current Form 20-F on file with the US Securities and Exchange 
Commission. Should one or more of these risks or uncertainties materialize, or should 
underlying assumptions prove incorrect, actual results may vary materially from those 
anticipated, believed, estimated or expected. Novartis is providing the information in this 
press release as of this date and does not undertake any obligation to update any 
forward-looking statements contained in this press release as a result of new 
information, future events or otherwise. 
4/4 
